Endophthalmitis

Infectious Disease MONDO:0016047 Pathograph 20 Show in embeddings browser eye infectious disorder inflammatory disease

Sight-threatening inflammation of the intraocular cavities (aqueous and vitreous humor), usually caused by microbial invasion of the eye. The eye is an immune-privileged site; once that privilege is breached and organisms gain access to the vitreous cavity, the host's own neutrophil- and cytokine-driven inflammatory response to the pathogen becomes a second, largely independent driver of retinal damage, which is why the inflammatory cascade can produce tissue destruction that exceeds the direct damage caused by the microorganisms themselves, and why adjunctive anti-inflammatory therapy (intravitreal corticosteroids) has been investigated alongside intravitreal antibiotics. Route of microbial entry defines the major clinically distinct forms, captured here as subtypes along a route-of-entry axis: postoperative (acute and chronic/delayed-onset), post-traumatic, bleb-associated, post-intravitreal-injection, and endogenous (hematogenous) endophthalmitis.

Ask OpenScientist

Ask a research question about Endophthalmitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

3
Mappings
10
Pathophys.
9
Phenotypes
20
Pathograph
6
Medical Actions
6
Subtypes
1
Trials
1
Models
1
Deep Research
🏷

Classifications

Harrison's Part
INFECTIOUS DISEASES
🔗

Mappings

MONDO
MONDO:0017202 acute endophthalmitis Not Yet Curated
skos:narrowMatch MONDO
MONDO:0017202 (acute endophthalmitis) is a narrower, temporal-onset concept subsumed by this entry's broader MONDO:0016047 (endophthalmitis) disease_term; too broad an axis (cutting across all routes of entry) to bind as a route-of-entry subtype_term, so it is captured here instead.
MONDO:0017203 chronic endophthalmitis Not Yet Curated
skos:narrowMatch MONDO
MONDO:0017203 (chronic endophthalmitis) is a narrower, temporal-onset concept subsumed by this entry's broader MONDO:0016047 (endophthalmitis) disease_term; too broad an axis (cutting across all routes of entry) to bind as a route-of-entry subtype_term, so it is captured here instead.
MONDO:0004863 purulent endophthalmitis Not Yet Curated
skos:narrowMatch MONDO
MONDO:0004863 (purulent endophthalmitis) is a narrower, suppurative-type concept subsumed by this entry's broader MONDO:0016047 (endophthalmitis) disease_term; too broad an axis to bind as a route-of-entry subtype_term, so it is captured here instead.
◆

Subtypes

6
Acute postoperative endophthalmitis
The most common clinical form, presenting within about a week of intraocular surgery (typically cataract surgery). Most commonly caused by coagulase-negative staphylococci (e.g. Staphylococcus epidermidis) introduced from the patient's own periocular/conjunctival flora at the time of surgery.
Show evidence (2 references)
PMID:23438028 SUPPORT Human Clinical
"acute post-cataract endophthalmitis complicates this procedure in c. 0.1% of cases"
Establishes acute postoperative endophthalmitis as a defined, quantified complication of cataract surgery.
PMID:23438028 SUPPORT Human Clinical
"Coagulase-negative staphylococci are the most common causes of post-cataract endophthalmitis, and these bacteria and viridans streptococci cause most cases of post-intravitreal anti-VEGF injection endophthalmitis, Bacillus cereus is a major cause of post-traumatic endophthalmitis, and..."
Identifies coagulase-negative staphylococci as the predominant organism in post-cataract (acute postoperative) endophthalmitis.
Chronic (delayed-onset) postoperative endophthalmitis
A low-grade, indolent form presenting weeks to months after intraocular surgery, classically associated with Cutibacterium acnes (formerly Propionibacterium acnes) sequestered within the capsular bag, producing a smoldering inflammation rather than the fulminant course of acute postoperative disease.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Chronic post-cataract endophthalmitis is usually caused by Propionibacterium acnes, and presents as a persistent low-grade inflammation in the anterior chamber."
Directly establishes Cutibacterium (Propionibacterium) acnes as the classic cause of chronic/delayed postoperative endophthalmitis with an indolent presentation.
Post-traumatic endophthalmitis
Follows open-globe (penetrating) ocular trauma, with organisms introduced directly by the injury, often including soil-associated or organic-material-associated organisms such as Bacillus cereus; retained intraocular foreign bodies and delayed primary repair further increase risk.
Show evidence (2 references)
PMID:23438028 SUPPORT Human Clinical
"Endophthalmitis occurs in 3–10% of cases after penetrating trauma to the eye"
Quantifies the incidence of endophthalmitis after open-globe trauma.
PMID:23438028 SUPPORT Human Clinical
"Bacillus cereus is a major pathogen in post-traumatic endophthalmitis, and causes a fulminant infection with very poor visual outcome"
Establishes Bacillus cereus as the characteristic, especially virulent, organism in post-traumatic endophthalmitis.
Bleb-associated (blebitis-related) endophthalmitis
A delayed complication of filtering (trabeculectomy) glaucoma surgery, in which the thin, avascular filtering bleb provides a chronic portal of entry for conjunctival organisms, often streptococcal species, and can occur years after the original surgery.
Show evidence (2 references)
PMID:23438028 SUPPORT Human Clinical
"Because only conjunctiva separates the ocular surface flora from the aqueous humor at the bleb, endophthalmitis may occur at any time. The risk of endophthalmitis is c. 1.3% per patient-year"
Explains the bleb-specific anatomical vulnerability and quantifies the annual risk of bleb-associated endophthalmitis.
PMID:23438028 SUPPORT Human Clinical
"Streptococci, including Streptococcus pneumoniae, cause 50% of cases."
Identifies streptococci, notably Streptococcus pneumoniae, as the predominant organisms in bleb-associated endophthalmitis.
Post-intravitreal-injection endophthalmitis
A rare but recognized complication of intravitreal injection of anti-VEGF and other therapeutic agents, with an incidence low enough per injection that its overall clinical burden is driven by the very high volume of injections performed.
Show evidence (2 references)
PMID:23438028 SUPPORT Human Clinical
"The rate of endophthalmitis per injection is low, with reported rates varying from 0.025% to 0.2%"
Quantifies the low per-injection risk of this subtype.
PMID:23438028 SUPPORT Human Clinical
"Coagulase-negative staphylococci cause c. 60% of cases and viridans streptococci cause 25%"
Quantifies the organism distribution in post-intravitreal-injection endophthalmitis, noting the comparatively higher streptococcal share.
Endogenous (hematogenous) endophthalmitis
Results from hematogenous seeding of the eye during bacteremia or fungemia from a distant source (e.g. endocarditis, urinary tract infection, indwelling catheter, hepatic abscess) rather than direct inoculation. Candida species are a leading cause in the fungal endogenous route; see Invasive_Candidiasis.yaml, which curates Candida chorioretinitis/endophthalmitis as a metastatic complication of candidemia rather than duplicating that content here.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Endogenous bacterial endophthalmitis arises from bacteraemic seeding of the eye. Endocarditis, usually caused by S. aureus or streptococci, accounts for 40% of endogenous endophthalmitis cases in the USA"
Establishes hematogenous seeding as the defining mechanism of endogenous endophthalmitis and quantifies endocarditis as a leading source in the USA.
⚙

Pathophysiology

10
Breach of the Blood-Ocular Barrier and Loss of Immune Privilege
The eye is an immune-privileged site maintained in part by the blood-aqueous and blood-retinal barriers, which normally limit infiltration of systemic immune cells into the intraocular cavities. Surgical incision, penetrating trauma, a filtering bleb, an intravitreal injection needle track, or hematogenous seeding each provide a route by which this barrier is breached and organisms gain direct access to the aqueous and vitreous humor.
Downstream
Intravitreal Microbial Proliferation Once organisms cross the breached barrier into the vitreous cavity, the compartment's low baseline immune surveillance permits microbial proliferation before an effective host response is mounted.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"Anatomically, the eye is normally protected from infection by several defense mechanisms, including an intact corneal epithelium, conjunctival immune surveillance, tear-film antimicrobial components, and the blood–aqueous and blood–retinal barriers. These barriers maintain ocular immune..."
Establishes the anatomical/immunological barriers whose breach defines the entry point of the disease.
Intravitreal Microbial Proliferation
Bacteria or fungi replicate within the vitreous cavity. The organism identity differs systematically by route of entry (coagulase-negative staphylococci in acute postoperative disease, Cutibacterium acnes in chronic postoperative disease, Bacillus cereus in post-traumatic disease, streptococci in bleb-associated and post-injection disease, and Staphylococcus aureus, streptococci, or Candida in endogenous disease), which is why empirical antibiotic selection is route-of-entry-dependent.
Downstream
Bacterial Peptidoglycan Precursor and Lipid II Synthesis (Vancomycin Target) Growth and division of the proliferating gram-positive organisms depends on ongoing peptidoglycan cell-wall synthesis, the step inhibited by empirical intravitreal vancomycin.
Bacterial Peptidoglycan Cross-Linking by Penicillin-Binding Proteins (Beta-Lactam Target) Growth of gram-negative and additional gram-positive organisms also depends on PBP-mediated peptidoglycan cross-linking, the step inhibited by empirical intravitreal ceftazidime.
Bacterial mRNA Translation by the Ribosome (Aminoglycoside Target) As an alternative to ceftazidime for gram-negative coverage, empirical therapy may instead inhibit bacterial ribosomal translation with intravitreal amikacin.
Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation Microbial replication and the release of pathogen-associated molecular patterns trigger an intense innate immune response within the confined intraocular space.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Coagulase-negative staphylococci are the most common causes of post-cataract endophthalmitis, and these bacteria and viridans streptococci cause most cases of post-intravitreal anti-VEGF injection endophthalmitis, Bacillus cereus is a major cause of post-traumatic endophthalmitis, and..."
Summarizes the route-of-entry-dependent organism spectrum that this node generalizes over.
Bacterial Peptidoglycan Precursor and Lipid II Synthesis (Vancomycin Target)
Gram-positive organisms causing endophthalmitis (coagulase-negative staphylococci, Cutibacterium acnes, streptococci) assemble the lipid II peptidoglycan precursor terminating in a D-Ala-D-Ala dipeptide. Glycopeptides such as vancomycin bind and sequester this exposed D-Ala-D-Ala terminus, blocking peptidoglycan polymerization. This is the fungus- and host-cell-independent, bacteria-specific vulnerability exploited by empirical intravitreal vancomycin.
Peptidoglycan Biosynthetic Process GO:0009252 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Peptidoglycan Biosynthetic Process (GO:0009252). GO:0009252 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:18302341 SUPPORT In Vitro
"the antimicrobial activity of other vancosamine-modified glycopeptides depends upon both d-Ala-d-Ala stem-terminus recognition (primary binding site) and stem-bridge recognition (secondary binding site)."
Solid-state NMR study confirming that glycopeptide antibiotics including vancomycin act by recognizing the D-Ala-D-Ala stem terminus of the peptidoglycan precursor.
Bacterial Peptidoglycan Cross-Linking by Penicillin-Binding Proteins (Beta-Lactam Target)
Penicillin-binding protein (PBP) transpeptidases cross-link peptidoglycan peptide stems to give the bacterial cell wall its load-bearing strength. Beta-lactams such as the third-generation cephalosporin ceftazidime acylate the PBP active-site serine and irreversibly block this cross-linking, the target exploited by empirical intravitreal ceftazidime for gram-negative and additional gram-positive coverage.
Peptidoglycan-Based Cell Wall Biogenesis GO:0009273 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Peptidoglycan-Based Cell Wall Biogenesis (GO:0009273). GO:0009273 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:22203377 SUPPORT Other
"Peptidoglycan synthesis requires glycosyltransferases (GTases) to polymerize the glycan chains and DD-transpeptidases (DD-TPases) to crosslink the peptides"
Review establishing that peptidoglycan cross-linking by DD-transpeptidases (PBPs) is a required step of cell-wall synthesis, the beta-lactam target. Evidence source is OTHER as this is a review article.
Bacterial mRNA Translation by the Ribosome (Aminoglycoside Target)
The bacterial 70S ribosome translates mRNA into protein. Aminoglycosides such as amikacin bind the 30S subunit and cause misreading, a bactericidal effect. Amikacin is used as an alternative to ceftazidime for empirical gram-negative coverage in endophthalmitis, though repeated intravitreal injection is avoided owing to retinal toxicity.
Translation GO:0006412 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Translation (GO:0006412). GO:0006412 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:24336183 SUPPORT Other
"The ribosome is one of the main antibiotic targets in the bacterial cell."
Review establishing the bacterial ribosome as a principal antibiotic target, the step this node represents. Evidence source is OTHER as this is a review article.
PMID:23438028 SUPPORT Human Clinical
"intravitreal vancomycin 1 mg/0.1 mL normal saline plus either ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL"
Documents amikacin as the empirically used alternative to ceftazidime in endophthalmitis therapy.
Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation
Resident and infiltrating cells release pro-inflammatory cytokines and chemokines that recruit large numbers of neutrophils into the aqueous and vitreous. This is the mechanistic thread distinct from direct microbial invasion: the intensity of the intraocular inflammatory response, not organism burden alone, is a principal driver of tissue injury, and elevated intravitreal cytokine levels correlate with disease severity in patients.
Neutrophil Chemotaxis GO:0030593 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Neutrophil Chemotaxis (GO:0030593). GO:0030593 is a biological process from the Gene Ontology.
Animal models
Mouse TLR4-dependent retinal inflammatory response in Bacillus cereus endophthalmitis Mouse recapitulates Intravitreal Bacillus cereus challenge in mice reproduces TLR4-dependent upregulation of neutrophil-recruiting chemokines in the retina, recapitulating the innate-immune amplification arm of this node.
Downstream
Neutrophil- and Cytokine-Mediated Retinal Toxicity Activated neutrophils release proteolytic enzymes and reactive oxygen species, and the cytokine milieu itself contributes to retinal damage, producing an inflammatory cascade whose tissue destruction can exceed that caused by the organism alone.
Show evidence (2 references)
PMID:30296277 SUPPORT Human Clinical
"Our results demonstrated elevated expression of 16 mediators such as GCSF, GRO, IFN-γ, IL-1α, IL-1β, IL-1 RA, IL-6, IL-8, IP-10, MCP-1, MCP-3, MIP-1α, IL-1β, TGF-α, TNF-α in patients with culture positive endophthalmitis."
Human vitreous-sample study demonstrating the pro-inflammatory cytokine and chemokine elevation this node describes, and linking it to disease severity.
PMID:29661181 SUPPORT Model Organism
"Genes related to acute inflammation and inflammatory cell recruitment including CXCL1 (KC), CXCL2 (MIP2-α), CXCL10 (IP-10), CCL2 (MCP1), and CCL3 (MIP1-α)) were significantly upregulated 5-fold or greater in C57BL/6 J retinas."
Mouse model of Bacillus cereus endophthalmitis showing TLR4-dependent upregulation of neutrophil-recruiting chemokines in the retina during infection.
Neutrophil- and Cytokine-Mediated Retinal Toxicity
Neutrophil-derived proteases and reactive oxygen species, together with sustained pro-inflammatory cytokine signaling, damage the retina and underlying retinal pigment epithelium. Current therapeutics are often unable to fully mitigate this damaging inflammation independently of antimicrobial killing, which is the rationale for investigating adjunctive intravitreal corticosteroids alongside intravitreal antibiotics: the corticosteroid targets host-driven inflammatory injury rather than the organism itself, although the clinical evidence for benefit remains limited and low-certainty.
Downstream
Irreversible Retinal Structural Damage and Vision Loss Sustained neutrophilic and cytokine-driven injury to the retina and retinal pigment epithelium produces structural damage that does not reverse even with organism eradication.
Show evidence (1 reference)
PMID:29661181 SUPPORT Model Organism
"Because current therapeutics are often unsuccessful in mitigating damaging inflammation during endophthalmitis, more rational targets are needed."
Directly motivates the rationale that host inflammation, separate from antimicrobial therapy, is an undertreated driver of damage in this disease.
Irreversible Retinal Structural Damage and Vision Loss
The combination of direct microbial toxicity and host-driven inflammatory injury produces structural retinal damage that is the proximate cause of the poor visual outcomes characteristic of endophthalmitis, even among eyes in which the infection is microbiologically cured. Prompt vitrectomy, which surgically debrides the infected and inflamed vitreous, improves outcomes in the most severely affected eyes.
Downstream
Retinal Necrosis, Vascular Occlusion, and Panophthalmitis Without timely and effective treatment, structural retinal damage escalates to frank retinal necrosis, occlusion of retinal vasculature, and extension of infection beyond the globe.
Show evidence (2 references)
PMID:31424768 SUPPORT Human Clinical
"The condition is a fulminant infection that can cause profound, irreversible vision loss within hours to days if not promptly recognized and treated."
Establishes the irreversibility and time-criticality of the tissue damage.
PMID:23438028 SUPPORT Human Clinical
"Vitrectomy decreased the rate of severe vision loss from 47% (tap group) to 20% (vitrectomy group) in patients who presented with the worst vision (light perception only)."
Reports the Endophthalmitis Vitrectomy Study result showing that surgical debridement of the vitreous reduces severe vision loss in the most severely affected eyes.
Retinal Necrosis, Vascular Occlusion, and Panophthalmitis
Escalating, unchecked intraocular inflammation and direct microbial invasion produce retinal necrosis and occlusion of the retinal vasculature, and infection may extend beyond the globe into the orbital tissues as panophthalmitis. HPO has no term for panophthalmitis or for infection-associated retinal necrosis as distinct from the specific viral acute retinal necrosis syndrome (HP:6001370), so this node is not bound to a phenotype_term; the end-stage anatomical outcome is captured as the Phthisis Bulbi phenotype below.
Downstream
Phthisis Bulbi and Loss of the Eye Progression of untreated retinal necrosis, vascular occlusion, and panophthalmitis leads to end-stage globe destruction.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"As inflammation intensifies, retinal necrosis, vascular occlusion, and panophthalmitis may ensue."
Directly documents retinal necrosis, vascular occlusion, and panophthalmitis as sequential complications of intensifying intraocular inflammation.
Phthisis Bulbi and Loss of the Eye
End-stage, irreversible shrinkage and disorganization of the globe (phthisis bulbi), or outright loss of the eye, represents the most severe anatomical outcome of untreated or inadequately treated endophthalmitis.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"Without timely intervention, permanent visual impairment, phthisis bulbi, or even loss of the eye may occur."
Directly documents phthisis bulbi and loss of the eye as the end-stage anatomical outcomes of untreated endophthalmitis.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Endophthalmitis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Cardiovascular 1
Conjunctival Injection VERY_FREQUENT Conjunctival hyperemia HP:0030953 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Conjunctival hyperemia (HP:0030953). HP:0030953 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"decreased vision (95%), red eye (80%), and eye pain (75%)"
Reports red eye (conjunctival injection) in 80% of acute postoperative endophthalmitis cases, within the VERY_FREQUENT (80-99%) band. The source sentence scopes this figure to acute postoperative disease specifically, hence the subtype tag.
Eye 3
Decreased Vision VERY_FREQUENT Visual impairment HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
Sequelae: Phthisis Bulbi
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"decreased vision (95%), red eye (80%), and eye pain (75%)"
Reports decreased vision in 95% of acute postoperative endophthalmitis cases, within the VERY_FREQUENT (80-99%) band. The source sentence scopes this figure to acute postoperative disease specifically, hence the subtype tag.
Photophobia HP:0000613 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"Initial symptoms typically include ocular pain, decreased vision, redness, photophobia, and floaters."
Documents photophobia as an initial presenting symptom.
Vitreous Floaters HP:0100832 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vitreous floaters (HP:0100832). HP:0100832 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"Initial symptoms typically include ocular pain, decreased vision, redness, photophobia, and floaters."
Documents floaters as an initial presenting symptom.
Constitutional 1
Eye Pain FREQUENT Ocular pain HP:0200026 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ocular pain (HP:0200026). HP:0200026 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"decreased vision (95%), red eye (80%), and eye pain (75%)"
Reports eye pain in 75% of acute postoperative endophthalmitis cases, within the FREQUENT (30-79%) band. The source sentence scopes this figure to acute postoperative disease specifically, hence the subtype tag.
Other 4
Hypopyon VERY_FREQUENT HP:0031615 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypopyon (HP:0031615). HP:0031615 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"a hypopyon is present in >80% of cases"
Reports hypopyon in over 80% of acute postoperative endophthalmitis cases, within the VERY_FREQUENT (80-99%) band. The source sentence scopes this figure to acute postoperative disease specifically, hence the subtype tag.
Vitritis HP:0011531 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Vitritis (HP:0011531). HP:0011531 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"On examination, clinicians may observe conjunctival injection, corneal edema, anterior chamber cells and flare, hypopyon, vitritis, and reduced fundus visibility."
Documents vitritis as a characteristic examination finding.
Corneal Edema Corneal stromal edema HP:0012040 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Corneal edema, annotated with Corneal stromal edema (HP:0012040). HP:0012040 is a phenotype from the Human Phenotype Ontology.
The cited source reports generic "corneal edema" without specifying the corneal layer involved; HP:0012040 (Corneal stromal edema) is the closest available HPO term, but is narrower than the source claim (HPO also has HP:6001182 Corneal epithelial edema, and no unqualified "corneal edema" parent term). Binding to the stromal-specific term is a known over-specification, kept because HPO offers no generic alternative.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"On examination, clinicians may observe conjunctival injection, corneal edema, anterior chamber cells and flare, hypopyon, vitritis, and reduced fundus visibility."
Documents corneal edema as a characteristic examination finding.
Phthisis Bulbi HP:0000667 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Phthisis bulbi (HP:0000667). HP:0000667 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31424768 SUPPORT Human Clinical
"Without timely intervention, permanent visual impairment, phthisis bulbi, or even loss of the eye may occur."
Documents phthisis bulbi as an end-stage anatomical outcome of untreated endophthalmitis.
💊

Medical Actions

6
Intravitreal Vancomycin
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: vancomycin CHEBI:28001 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses vancomycin (CHEBI:28001). CHEBI:28001 is a therapeutic agent from Chemical Entities of Biological Interest.
Empirical intravitreal antibiotic covering gram-positive organisms (including coagulase-negative staphylococci), the predominant pathogens in postoperative endophthalmitis.
Mechanism Target:
INHIBITS Bacterial Peptidoglycan Precursor and Lipid II Synthesis (Vancomycin Target) — Vancomycin sequesters the D-Ala-D-Ala terminus of the lipid II peptidoglycan precursor, blocking cell-wall synthesis in the predominantly gram-positive organisms causing endophthalmitis.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"intravitreal vancomycin 1 mg/0.1 mL normal saline plus either ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL"
Documents intravitreal vancomycin as first-line empirical therapy.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"intravitreal vancomycin 1 mg/0.1 mL normal saline plus either ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL"
Documents intravitreal vancomycin as first-line empirical broad-spectrum therapy.
Intravitreal Ceftazidime
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: ceftazidime CHEBI:3508 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ceftazidime (CHEBI:3508). CHEBI:3508 is a therapeutic agent from Chemical Entities of Biological Interest.
Empirical intravitreal antibiotic covering gram-negative organisms, combined with intravitreal vancomycin for broad-spectrum coverage pending culture results.
Mechanism Target:
INHIBITS Bacterial Peptidoglycan Cross-Linking by Penicillin-Binding Proteins (Beta-Lactam Target) — Ceftazidime acylates the penicillin-binding protein active site, blocking peptidoglycan cross-linking to provide gram-negative and additional gram-positive coverage.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"intravitreal vancomycin 1 mg/0.1 mL normal saline plus either ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL"
Documents intravitreal ceftazidime as first-line empirical therapy.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"intravitreal vancomycin 1 mg/0.1 mL normal saline plus either ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL"
Documents intravitreal ceftazidime as first-line empirical broad-spectrum therapy.
Intravitreal Amikacin
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: amikacin CHEBI:2637 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses amikacin (CHEBI:2637). CHEBI:2637 is a therapeutic agent from Chemical Entities of Biological Interest.
Alternative empirical intravitreal antibiotic for gram-negative coverage when ceftazidime is not used; repeated injection is avoided owing to concerns about retinal toxicity.
Mechanism Target:
INHIBITS Bacterial mRNA Translation by the Ribosome (Aminoglycoside Target) — Amikacin binds the bacterial 30S ribosomal subunit, causing translational misreading and bactericidal effects in gram-negative organisms.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Repeated injections of amikacin are avoided, owing to concerns about retinal toxicity."
Documents intravitreal amikacin as an empirical alternative and notes its dose-limiting retinal toxicity.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Repeated injections of amikacin are avoided, owing to concerns about retinal toxicity."
Documents intravitreal amikacin as an empirical alternative to ceftazidime, with a dose-limiting retinal-toxicity caveat.
Intravitreal Corticosteroid
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: dexamethasone CHEBI:41879 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dexamethasone (CHEBI:41879). CHEBI:41879 is a therapeutic agent from Chemical Entities of Biological Interest.
Adjunctive intravitreal corticosteroid (dexamethasone) investigated alongside intravitreal antibiotics to target the neutrophil- and cytokine-driven retinal toxicity that can persist independently of antimicrobial killing. Evidence for benefit is low-certainty: a Cochrane review found current evidence on adjunctive steroid therapy versus antibiotics alone to be inadequate, though a combined analysis of two small trials suggested a higher probability of a good visual outcome at three months with adjunctive dexamethasone.
Mechanism Target:
INHIBITS Neutrophil- and Cytokine-Mediated Retinal Toxicity — Intravitreal dexamethasone is intended to suppress neutrophil- and cytokine-driven inflammatory injury to the retina independently of antimicrobial action against the causative organism.
Show evidence (1 reference)
PMID:28225198 SUPPORT Human Clinical
"Low-certainty evidence from two studies showed that a higher proportion of participants who received adjunctive dexamethasone had a good visual outcome (Snellen visual acuity 6/6 to 6/18) at three months compared with those in the antibiotics-alone group (RR 1.95, 95% CI 1.05 to 3.60; 60 participants)."
Cochrane systematic review reporting low-certainty evidence of visual-outcome benefit from adjunctive intravitreal dexamethasone; supports the mechanistic rationale but the review's overall conclusion (inadequate evidence) is captured in the treatment description rather than overstated here.
Show evidence (1 reference)
PMID:28225198 SUPPORT Human Clinical
"Current evidence on the effectiveness of adjunctive steroid therapy versus antibiotics alone in the management of acute endophthalmitis after intraocular surgery is inadequate."
Cochrane review's own authors' conclusion, quoted to keep the treatment entry honest about the limited certainty of current evidence for this adjunctive therapy.
Pars Plana Vitrectomy
Action: VitrectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Vitrectomy (NCIT:C50837). NCIT:C50837 is a clinical intervention from the NCI Thesaurus. NCIT:C50837
Surgical removal of infected, inflamed vitreous, indicated for eyes with the most severe vision loss at presentation.
Mechanism Target:
INHIBITS Intravitreal Microbial Proliferation — Vitrectomy surgically debrides the infected vitreous humor, physically removing the microbial and inflammatory-mediator reservoir, similar to draining an abscess.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Vitrectomy decreased the rate of severe vision loss from 47% (tap group) to 20% (vitrectomy group) in patients who presented with the worst vision (light perception only)."
Reports the Endophthalmitis Vitrectomy Study finding that vitrectomy reduces severe vision loss in the most severely affected eyes.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Vitrectomy decreased the rate of severe vision loss from 47% (tap group) to 20% (vitrectomy group) in patients who presented with the worst vision (light perception only)."
Endophthalmitis Vitrectomy Study finding, as reported in this review, establishing the clinical benefit of vitrectomy in the most severely affected eyes.
Systemic Antibiotic Therapy for Endogenous and Fungal Disease
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Systemic antimicrobial therapy directed at the underlying source of bacteremia or fungemia. Required in endogenous endophthalmitis (which is seeded hematogenously from an extraocular source) and used adjunctively in exogenous fungal endophthalmitis; intravitreal antibiotics remain necessary regardless, since systemic therapy alone does not adequately treat the intraocular infection.
Mechanism Target:
INHIBITS Intravitreal Microbial Proliferation — Eliminating the extraocular bacteremic or fungemic source reduces continued hematogenous seeding of the vitreous cavity in endogenous disease, complementing intravitreal antibiotics, which act on the organisms already present intraocularly; systemic therapy alone does not effectively treat the established intraocular infection.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Treatment of the underlying source of bacteraemia with systemic antibiotics is necessary, but this will not effectively treat the endophthalmitis: intravitreal antibiotics and, usually, a vitrectomy are necessary."
Documents that systemic antibiotics treat the bacteremic source of continued seeding while intravitreal antibiotics act on the established intraocular infection itself.
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Systemic antibiotics are necessary to treat the underlying infection in endogenous endophthalmitis, and as adjunctive therapy in exogenous fungal endophthalmitis."
States the indication for systemic (as opposed to intravitreal-only) antimicrobial therapy in endogenous and exogenous fungal disease.
🔬

Biochemical Markers

1
Vitreous Pro-Inflammatory Cytokine Elevation (INCREASED)
Context: Elevated vitreous levels of multiple pro-inflammatory cytokines and chemokines correlate with disease severity in culture-positive infectious endophthalmitis.
Pathograph Readouts
Readout Of Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation Positive
Show evidence (1 reference)
PMID:30296277 SUPPORT Human Clinical
"Our results demonstrated elevated expression of 16 mediators such as GCSF, GRO, IFN-γ, IL-1α, IL-1β, IL-1 RA, IL-6, IL-8, IP-10, MCP-1, MCP-3, MIP-1α, IL-1β, TGF-α, TNF-α in patients with culture positive endophthalmitis."
Directly reports the vitreous cytokine/chemokine elevation this biomarker readout links to the neutrophil- and cytokine-driven inflammation pathophysiology node.
Show evidence (1 reference)
PMID:30296277 SUPPORT Human Clinical
"Our results demonstrated elevated expression of 16 mediators such as GCSF, GRO, IFN-γ, IL-1α, IL-1β, IL-1 RA, IL-6, IL-8, IP-10, MCP-1, MCP-3, MIP-1α, IL-1β, TGF-α, TNF-α in patients with culture positive endophthalmitis."
Human vitreous-sample study demonstrating pro-inflammatory cytokine/chemokine elevation as a disease-severity biomarker in infectious endophthalmitis.
🔬

Diagnosis

2
Intraocular Fluid Culture
Endophthalmitis is a clinical diagnosis supported by microbiological culture of intraocular fluid (vitreous humor via vitrectomy or needle aspirate, or aqueous humor via needle aspirate). A negative culture occurs in a substantial minority of cases and does not exclude the diagnosis; the principal differential diagnosis is sterile intraocular inflammation (e.g. a postoperative reaction or toxic anterior segment syndrome).
microbial culture procedure NCIT:C25300 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:23438028 SUPPORT Human Clinical
"Endophthalmitis is a clinical diagnosis, supported by culture of intra-ocular fluids, although a negative culture occurs in 30% of cases. The differential diagnosis is sterile intra-ocular inflammation."
Establishes endophthalmitis as a clinical diagnosis supported by intraocular fluid culture, quantifies the negative-culture rate, and names the principal differential diagnosis.
PMID:23438028 SUPPORT Human Clinical
"Vitreous cultures are more likely to be positive after vitrectomy than vitreous aspirate (90% vs. 75%); aqueous cultures are positive in 40%"
Quantifies culture yield by sampling method and fluid compartment (vitrectomy vs. vitreous aspirate vs. aqueous aspirate).
Gram Stain of Intraocular Fluid
Gram staining of the intraocular fluid sample obtained for culture provides rapid, though imperfectly sensitive, identification of the infecting organism class pending culture results.
Gram staining method NCIT:C23014 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Gram stains are positive in 40–50% of cases."
Quantifies the diagnostic yield of Gram staining of intraocular fluid.
🦠

Infectious Agent

4
Coagulase-Negative Staphylococci
The leading cause of acute postoperative endophthalmitis, introduced from the patient's own periocular flora at the time of intraocular surgery, and the leading cause of post-intravitreal-injection endophthalmitis.
Staphylococcus epidermidis NCBITaxon:1282 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Coagulase-negative staphylococci are the most common causes of post-cataract endophthalmitis"
Directly identifies coagulase-negative staphylococci as the predominant organism.
Cutibacterium acnes
The classic cause of chronic (delayed-onset) postoperative endophthalmitis, sequestered within the lens capsular bag and producing an indolent course.
Cutibacterium acnes NCBITaxon:1747 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Chronic post-cataract endophthalmitis is usually caused by Propionibacterium acnes"
Establishes Cutibacterium (Propionibacterium) acnes as the classic cause of chronic postoperative endophthalmitis.
Bacillus cereus
A major and especially virulent cause of post-traumatic endophthalmitis, typically introduced via soil- or organic-material-contaminated penetrating injury.
Bacillus cereus NCBITaxon:1396 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Bacillus cereus is a major pathogen in post-traumatic endophthalmitis, and causes a fulminant infection with very poor visual outcome"
Establishes Bacillus cereus as the characteristic post-traumatic pathogen.
Streptococcus pneumoniae
A leading cause of bleb-associated endophthalmitis, entering via the thin, avascular filtering bleb.
Streptococcus pneumoniae NCBITaxon:1313 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:23438028 SUPPORT Human Clinical
"Streptococci, including Streptococcus pneumoniae, cause 50% of cases."
Identifies Streptococcus pneumoniae as a leading bleb-associated pathogen.
🔬

Clinical Trials

1
NCT00000130 PHASE_III COMPLETED
Randomized controlled trial (the Endophthalmitis Vitrectomy Study, EVS) establishing the role of initial pars plana vitrectomy, and of intravenous antibiotics, in the management of postoperative bacterial endophthalmitis. Underpins the vitrectomy indication and outcome data already cited in this entry's treatments and pathophysiology from PMID:23438028's summary of the trial's results.
Target Phenotypes: Visual impairment HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Visual impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT00000130 SUPPORT Human Clinical
"To determine the role of initial pars plana vitrectomy in the management of postoperative bacterial endophthalmitis."
Registry record of the EVS trial's stated objective, establishing the trial identity underpinning the already-cited vitrectomy indication.
🐁

Animal Models

1
Mouse TLR4-dependent retinal inflammatory response in Bacillus cereus endophthalmitis
Species
Mouse
Genotype
C57BL/6J (wild-type); TLR4-deficient comparator
Publication
PMID:29661181
Pathograph links
Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation recapitulates fidelity: moderate Intravitreal Bacillus cereus challenge in mice reproduces TLR4-dependent upregulation of neutrophil-recruiting chemokines in the retina, recapitulating the innate-immune amplification arm of this node.
Limitations: Bacillus cereus endophthalmitis is a single, particularly virulent post-traumatic pathogen; the murine retinal chemokine response may not generalize to the coagulase-negative staphylococcal and streptococcal infections that predominate in postoperative and bleb-associated human disease.
Readouts
Retinal chemokine gene expression
Direction: INCREASED
Interpretation: Structural/molecular correlate of neutrophil-recruiting chemokine upregulation in this model.
Show evidence (1 reference)
PMID:29661181 SUPPORT Model Organism
"Genes related to acute inflammation and inflammatory cell recruitment including CXCL1 (KC), CXCL2 (MIP2-α), CXCL10 (IP-10), CCL2 (MCP1), and CCL3 (MIP1-α)) were significantly upregulated 5-fold or greater in C57BL/6 J retinas."
Reports the quantitative retinal chemokine upregulation measured in this model.
Show evidence (1 reference)
PMID:29661181 SUPPORT Model Organism
"Genes related to acute inflammation and inflammatory cell recruitment including CXCL1 (KC), CXCL2 (MIP2-α), CXCL10 (IP-10), CCL2 (MCP1), and CCL3 (MIP1-α)) were significantly upregulated 5-fold or greater in C57BL/6 J retinas."
Supports treating this model as informative for the neutrophil- and cytokine-driven inflammation node.
{ }

Source YAML

click to show 
name: Endophthalmitis
creation_date: "2026-08-26T23:26:14Z"
category: Infectious Disease
disease_term:
  preferred_term: endophthalmitis
  term:
    id: MONDO:0016047
    label: endophthalmitis
description: >-
  Sight-threatening inflammation of the intraocular cavities (aqueous and
  vitreous humor), usually caused by microbial invasion of the eye. The eye is
  an immune-privileged site; once that privilege is breached and organisms
  gain access to the vitreous cavity, the host's own neutrophil- and
  cytokine-driven inflammatory response to the pathogen becomes a second,
  largely independent driver of retinal damage, which is why the inflammatory
  cascade can produce tissue destruction that exceeds the direct damage
  caused by the microorganisms themselves, and why adjunctive
  anti-inflammatory therapy (intravitreal corticosteroids) has been
  investigated alongside intravitreal antibiotics. Route of microbial entry
  defines the major clinically distinct forms, captured here as subtypes
  along a route-of-entry axis: postoperative (acute and chronic/delayed-onset),
  post-traumatic, bleb-associated, post-intravitreal-injection, and endogenous
  (hematogenous) endophthalmitis.
parents:
- eye infectious disorder
- inflammatory disease
classifications:
  harrisons_chapter:
  - classification_value: INFECTIOUS_DISEASES
    evidence:
    - reference: PMID:23438028
      reference_title: Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Endophthalmitis means bacterial or fungal infection inside the eye
        involving the vitreous and/or aqueous humors.
      explanation: >-
        Endophthalmitis is fundamentally a microbial infectious disease of
        the eye, placing it in Harrison's Infectious Diseases Part.
has_subtypes:
- name: Acute Postoperative
  display_name: Acute postoperative endophthalmitis
  description: >-
    The most common clinical form, presenting within about a week of
    intraocular surgery (typically cataract surgery). Most commonly caused by
    coagulase-negative staphylococci (e.g. Staphylococcus epidermidis)
    introduced from the patient's own periocular/conjunctival flora at the
    time of surgery.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      acute post-cataract endophthalmitis complicates this procedure in c.
      0.1% of cases
    explanation: >-
      Establishes acute postoperative endophthalmitis as a defined,
      quantified complication of cataract surgery.
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Coagulase-negative staphylococci are the most common causes of
      post-cataract endophthalmitis, and these bacteria and viridans
      streptococci cause most cases of post-intravitreal anti-VEGF injection
      endophthalmitis, Bacillus cereus is a major cause of post-traumatic
      endophthalmitis, and Staphylococcus aureus and streptococci are
      important causes of endogenous endophthalmitis associated with
      endocarditis.
    explanation: >-
      Identifies coagulase-negative staphylococci as the predominant
      organism in post-cataract (acute postoperative) endophthalmitis.
- name: Chronic Postoperative
  display_name: Chronic (delayed-onset) postoperative endophthalmitis
  description: >-
    A low-grade, indolent form presenting weeks to months after intraocular
    surgery, classically associated with Cutibacterium acnes (formerly
    Propionibacterium acnes) sequestered within the capsular bag, producing a
    smoldering inflammation rather than the fulminant course of acute
    postoperative disease.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chronic post-cataract endophthalmitis is usually caused by
      Propionibacterium acnes, and presents as a persistent low-grade
      inflammation in the anterior chamber.
    explanation: >-
      Directly establishes Cutibacterium (Propionibacterium) acnes as the
      classic cause of chronic/delayed postoperative endophthalmitis with an
      indolent presentation.
- name: Post-Traumatic
  display_name: Post-traumatic endophthalmitis
  description: >-
    Follows open-globe (penetrating) ocular trauma, with organisms introduced
    directly by the injury, often including soil-associated or
    organic-material-associated organisms such as Bacillus cereus; retained
    intraocular foreign bodies and delayed primary repair further increase risk.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Endophthalmitis occurs in 3–10% of cases after penetrating trauma to
      the eye
    explanation: Quantifies the incidence of endophthalmitis after open-globe trauma.
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bacillus cereus is a major pathogen in post-traumatic endophthalmitis,
      and causes a fulminant infection with very poor visual outcome
    explanation: >-
      Establishes Bacillus cereus as the characteristic, especially
      virulent, organism in post-traumatic endophthalmitis.
- name: Bleb-Associated
  display_name: Bleb-associated (blebitis-related) endophthalmitis
  description: >-
    A delayed complication of filtering (trabeculectomy) glaucoma surgery, in
    which the thin, avascular filtering bleb provides a chronic portal of
    entry for conjunctival organisms, often streptococcal species, and can
    occur years after the original surgery.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Because only conjunctiva separates the ocular surface flora from the
      aqueous humor at the bleb, endophthalmitis may occur at any time. The
      risk of endophthalmitis is c. 1.3% per patient-year
    explanation: >-
      Explains the bleb-specific anatomical vulnerability and quantifies the
      annual risk of bleb-associated endophthalmitis.
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Streptococci, including Streptococcus pneumoniae, cause 50% of cases."
    explanation: >-
      Identifies streptococci, notably Streptococcus pneumoniae, as the
      predominant organisms in bleb-associated endophthalmitis.
- name: Post-Intravitreal-Injection
  display_name: Post-intravitreal-injection endophthalmitis
  description: >-
    A rare but recognized complication of intravitreal injection of
    anti-VEGF and other therapeutic agents, with an incidence low enough per
    injection that its overall clinical burden is driven by the very high
    volume of injections performed.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rate of endophthalmitis per injection is low, with reported rates
      varying from 0.025% to 0.2%
    explanation: Quantifies the low per-injection risk of this subtype.
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Coagulase-negative staphylococci cause c. 60% of cases and viridans
      streptococci cause 25%
    explanation: >-
      Quantifies the organism distribution in post-intravitreal-injection
      endophthalmitis, noting the comparatively higher streptococcal share.
- name: Endogenous
  display_name: Endogenous (hematogenous) endophthalmitis
  description: >-
    Results from hematogenous seeding of the eye during bacteremia or
    fungemia from a distant source (e.g. endocarditis, urinary tract
    infection, indwelling catheter, hepatic abscess) rather than direct
    inoculation. Candida species are a leading cause in the fungal endogenous
    route; see Invasive_Candidiasis.yaml, which curates Candida
    chorioretinitis/endophthalmitis as a metastatic complication of
    candidemia rather than duplicating that content here.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Endogenous bacterial endophthalmitis arises from bacteraemic seeding of
      the eye. Endocarditis, usually caused by S. aureus or streptococci,
      accounts for 40% of endogenous endophthalmitis cases in the USA
    explanation: >-
      Establishes hematogenous seeding as the defining mechanism of
      endogenous endophthalmitis and quantifies endocarditis as a leading
      source in the USA.
pathophysiology:
- name: Breach of the Blood-Ocular Barrier and Loss of Immune Privilege
  role: trigger
  biological_scale: TISSUE
  description: >-
    The eye is an immune-privileged site maintained in part by the
    blood-aqueous and blood-retinal barriers, which normally limit
    infiltration of systemic immune cells into the intraocular cavities.
    Surgical incision, penetrating trauma, a filtering bleb, an intravitreal
    injection needle track, or hematogenous seeding each provide a route by
    which this barrier is breached and organisms gain direct access to the
    aqueous and vitreous humor.
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Anatomically, the eye is normally protected from infection by several
      defense mechanisms, including an intact corneal epithelium,
      conjunctival immune surveillance, tear-film antimicrobial components,
      and the blood–aqueous and blood–retinal barriers. These barriers
      maintain ocular immune privilege by limiting infiltration of systemic
      immune cells.
    explanation: >-
      Establishes the anatomical/immunological barriers whose breach defines
      the entry point of the disease.
  downstream:
  - target: Intravitreal Microbial Proliferation
    causal_link_type: DIRECT
    description: >-
      Once organisms cross the breached barrier into the vitreous cavity,
      the compartment's low baseline immune surveillance permits microbial
      proliferation before an effective host response is mounted.
    evidence:
    - reference: PMID:31424768
      reference_title: Bacterial Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The vitreous cavity, in particular, provides a relatively avascular
        and immunologically protected environment, allowing bacteria to
        multiply with minimal early immune containment.
      explanation: >-
        Directly connects barrier breach to unchecked early microbial
        proliferation within the vitreous cavity.
- name: Intravitreal Microbial Proliferation
  role: consequence
  biological_scale: CELLULAR
  description: >-
    Bacteria or fungi replicate within the vitreous cavity. The organism
    identity differs systematically by route of entry (coagulase-negative
    staphylococci in acute postoperative disease, Cutibacterium acnes in
    chronic postoperative disease, Bacillus cereus in post-traumatic
    disease, streptococci in bleb-associated and post-injection disease, and
    Staphylococcus aureus, streptococci, or Candida in endogenous disease),
    which is why empirical antibiotic selection is route-of-entry-dependent.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Coagulase-negative staphylococci are the most common causes of
      post-cataract endophthalmitis, and these bacteria and viridans
      streptococci cause most cases of post-intravitreal anti-VEGF injection
      endophthalmitis, Bacillus cereus is a major cause of post-traumatic
      endophthalmitis, and Staphylococcus aureus and streptococci are
      important causes of endogenous endophthalmitis associated with
      endocarditis.
    explanation: >-
      Summarizes the route-of-entry-dependent organism spectrum that this
      node generalizes over.
  downstream:
  - target: Bacterial Peptidoglycan Precursor and Lipid II Synthesis (Vancomycin Target)
    causal_link_type: DIRECT
    description: >-
      Growth and division of the proliferating gram-positive organisms
      depends on ongoing peptidoglycan cell-wall synthesis, the step
      inhibited by empirical intravitreal vancomycin.
  - target: Bacterial Peptidoglycan Cross-Linking by Penicillin-Binding Proteins (Beta-Lactam Target)
    causal_link_type: DIRECT
    description: >-
      Growth of gram-negative and additional gram-positive organisms also
      depends on PBP-mediated peptidoglycan cross-linking, the step
      inhibited by empirical intravitreal ceftazidime.
  - target: Bacterial mRNA Translation by the Ribosome (Aminoglycoside Target)
    causal_link_type: DIRECT
    description: >-
      As an alternative to ceftazidime for gram-negative coverage, empirical
      therapy may instead inhibit bacterial ribosomal translation with
      intravitreal amikacin.
  - target: Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation
    causal_link_type: DIRECT
    description: >-
      Microbial replication and the release of pathogen-associated molecular
      patterns trigger an intense innate immune response within the
      confined intraocular space.
    evidence:
    - reference: PMID:31424768
      reference_title: Bacterial Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Once bacterial proliferation reaches a critical threshold,
        pathogen-associated molecular patterns (PAMPs) trigger a robust
        inflammatory response mediated by cytokines, complement activation,
        and neutrophilic infiltration.
      explanation: >-
        Directly links microbial proliferation to the onset of the
        cytokine- and neutrophil-driven inflammatory cascade.
- name: Bacterial Peptidoglycan Precursor and Lipid II Synthesis (Vancomycin Target)
  role: therapeutic_vulnerability
  biological_scale: MOLECULAR
  conforms_to: "bacterial_cell_wall_synthesis_inhibition#Peptidoglycan Precursor and Lipid II Synthesis"
  description: >-
    Gram-positive organisms causing endophthalmitis (coagulase-negative
    staphylococci, Cutibacterium acnes, streptococci) assemble the lipid II
    peptidoglycan precursor terminating in a D-Ala-D-Ala dipeptide.
    Glycopeptides such as vancomycin bind and sequester this exposed
    D-Ala-D-Ala terminus, blocking peptidoglycan polymerization. This is the
    fungus- and host-cell-independent, bacteria-specific vulnerability
    exploited by empirical intravitreal vancomycin.
  biological_processes:
  - preferred_term: Peptidoglycan Biosynthetic Process
    term:
      id: GO:0009252
      label: peptidoglycan biosynthetic process
  evidence:
  - reference: PMID:18302341
    reference_title: >-
      Vancomycin derivative with damaged D-Ala-D-Ala binding cleft binds to
      cross-linked peptidoglycan in the cell wall of Staphylococcus aureus.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the antimicrobial activity of other vancosamine-modified glycopeptides
      depends upon both d-Ala-d-Ala stem-terminus recognition (primary
      binding site) and stem-bridge recognition (secondary binding site).
    explanation: >-
      Solid-state NMR study confirming that glycopeptide antibiotics
      including vancomycin act by recognizing the D-Ala-D-Ala stem terminus
      of the peptidoglycan precursor.
- name: Bacterial Peptidoglycan Cross-Linking by Penicillin-Binding Proteins (Beta-Lactam Target)
  role: therapeutic_vulnerability
  biological_scale: MOLECULAR
  conforms_to: "bacterial_cell_wall_synthesis_inhibition#Peptidoglycan Cross-Linking by Penicillin-Binding Proteins"
  description: >-
    Penicillin-binding protein (PBP) transpeptidases cross-link peptidoglycan
    peptide stems to give the bacterial cell wall its load-bearing strength.
    Beta-lactams such as the third-generation cephalosporin ceftazidime
    acylate the PBP active-site serine and irreversibly block this
    cross-linking, the target exploited by empirical intravitreal
    ceftazidime for gram-negative and additional gram-positive coverage.
  biological_processes:
  - preferred_term: Peptidoglycan-Based Cell Wall Biogenesis
    term:
      id: GO:0009273
      label: peptidoglycan-based cell wall biogenesis
  evidence:
  - reference: PMID:22203377
    reference_title: >-
      From the regulation of peptidoglycan synthesis to bacterial growth and
      morphology.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Peptidoglycan synthesis requires glycosyltransferases (GTases) to
      polymerize the glycan chains and DD-transpeptidases (DD-TPases) to
      crosslink the peptides
    explanation: >-
      Review establishing that peptidoglycan cross-linking by
      DD-transpeptidases (PBPs) is a required step of cell-wall synthesis,
      the beta-lactam target. Evidence source is OTHER as this is a review
      article.
- name: Bacterial mRNA Translation by the Ribosome (Aminoglycoside Target)
  role: therapeutic_vulnerability
  biological_scale: MOLECULAR
  conforms_to: "bacterial_protein_synthesis_inhibition#Bacterial mRNA Translation by the Ribosome"
  description: >-
    The bacterial 70S ribosome translates mRNA into protein. Aminoglycosides
    such as amikacin bind the 30S subunit and cause misreading, a
    bactericidal effect. Amikacin is used as an alternative to ceftazidime
    for empirical gram-negative coverage in endophthalmitis, though repeated
    intravitreal injection is avoided owing to retinal toxicity.
  biological_processes:
  - preferred_term: Translation
    term:
      id: GO:0006412
      label: translation
  evidence:
  - reference: PMID:24336183
    reference_title: Ribosome-targeting antibiotics and mechanisms of bacterial resistance.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The ribosome is one of the main antibiotic targets in the bacterial cell."
    explanation: >-
      Review establishing the bacterial ribosome as a principal antibiotic
      target, the step this node represents. Evidence source is OTHER as
      this is a review article.
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intravitreal vancomycin 1 mg/0.1 mL normal saline plus either
      ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL
    explanation: >-
      Documents amikacin as the empirically used alternative to ceftazidime
      in endophthalmitis therapy.
- name: Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation
  role: consequence
  biological_scale: TISSUE
  description: >-
    Resident and infiltrating cells release pro-inflammatory cytokines and
    chemokines that recruit large numbers of neutrophils into the aqueous
    and vitreous. This is the mechanistic thread distinct from direct
    microbial invasion: the intensity of the intraocular inflammatory
    response, not organism burden alone, is a principal driver of tissue
    injury, and elevated intravitreal cytokine levels correlate with disease
    severity in patients.
  biological_processes:
  - preferred_term: Neutrophil Chemotaxis
    term:
      id: GO:0030593
      label: neutrophil chemotaxis
  evidence:
  - reference: PMID:30296277
    reference_title: >-
      Elevated cytokine levels in vitreous as biomarkers of disease severity
      in infectious endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results demonstrated elevated expression of 16 mediators such as
      GCSF, GRO, IFN-γ, IL-1α, IL-1β, IL-1 RA, IL-6, IL-8, IP-10, MCP-1,
      MCP-3, MIP-1α, IL-1β, TGF-α, TNF-α in patients with culture positive
      endophthalmitis.
    explanation: >-
      Human vitreous-sample study demonstrating the pro-inflammatory
      cytokine and chemokine elevation this node describes, and linking it
      to disease severity.
  - reference: PMID:29661181
    reference_title: >-
      TLR4 modulates inflammatory gene targets in the retina during
      Bacillus cereus endophthalmitis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Genes related to acute inflammation and inflammatory cell recruitment
      including CXCL1 (KC), CXCL2 (MIP2-α), CXCL10 (IP-10), CCL2 (MCP1), and
      CCL3 (MIP1-α)) were significantly upregulated 5-fold or greater in
      C57BL/6 J retinas.
    explanation: >-
      Mouse model of Bacillus cereus endophthalmitis showing TLR4-dependent
      upregulation of neutrophil-recruiting chemokines in the retina during
      infection.
  downstream:
  - target: Neutrophil- and Cytokine-Mediated Retinal Toxicity
    causal_link_type: DIRECT
    description: >-
      Activated neutrophils release proteolytic enzymes and reactive oxygen
      species, and the cytokine milieu itself contributes to retinal
      damage, producing an inflammatory cascade whose tissue destruction can
      exceed that caused by the organism alone.
    evidence:
    - reference: PMID:31424768
      reference_title: Bacterial Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This inflammatory cascade contributes substantially to tissue
        destruction, often exceeding the direct damage caused by the
        microorganisms themselves.
      explanation: >-
        States directly that the host inflammatory cascade, not the
        organism, is often the larger contributor to tissue destruction.
- name: Neutrophil- and Cytokine-Mediated Retinal Toxicity
  role: consequence
  biological_scale: TISSUE
  description: >-
    Neutrophil-derived proteases and reactive oxygen species, together with
    sustained pro-inflammatory cytokine signaling, damage the retina and
    underlying retinal pigment epithelium. Current therapeutics are often
    unable to fully mitigate this damaging inflammation independently of
    antimicrobial killing, which is the rationale for investigating
    adjunctive intravitreal corticosteroids alongside intravitreal
    antibiotics: the corticosteroid targets host-driven inflammatory injury
    rather than the organism itself, although the clinical evidence for
    benefit remains limited and low-certainty.
  evidence:
  - reference: PMID:29661181
    reference_title: >-
      TLR4 modulates inflammatory gene targets in the retina during
      Bacillus cereus endophthalmitis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Because current therapeutics are often unsuccessful in mitigating
      damaging inflammation during endophthalmitis, more rational targets
      are needed.
    explanation: >-
      Directly motivates the rationale that host inflammation, separate
      from antimicrobial therapy, is an undertreated driver of damage in
      this disease.
  downstream:
  - target: Irreversible Retinal Structural Damage and Vision Loss
    causal_link_type: DIRECT
    description: >-
      Sustained neutrophilic and cytokine-driven injury to the retina and
      retinal pigment epithelium produces structural damage that does not
      reverse even with organism eradication.
- name: Irreversible Retinal Structural Damage and Vision Loss
  role: consequence
  biological_scale: TISSUE
  description: >-
    The combination of direct microbial toxicity and host-driven
    inflammatory injury produces structural retinal damage that is the
    proximate cause of the poor visual outcomes characteristic of
    endophthalmitis, even among eyes in which the infection is
    microbiologically cured. Prompt vitrectomy, which surgically debrides
    the infected and inflamed vitreous, improves outcomes in the most
    severely affected eyes.
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The condition is a fulminant infection that can cause profound,
      irreversible vision loss within hours to days if not promptly
      recognized and treated.
    explanation: Establishes the irreversibility and time-criticality of the tissue damage.
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vitrectomy decreased the rate of severe vision loss from 47% (tap
      group) to 20% (vitrectomy group) in patients who presented with the
      worst vision (light perception only).
    explanation: >-
      Reports the Endophthalmitis Vitrectomy Study result showing that
      surgical debridement of the vitreous reduces severe vision loss in the
      most severely affected eyes.
  downstream:
  - target: Retinal Necrosis, Vascular Occlusion, and Panophthalmitis
    causal_link_type: DIRECT
    description: >-
      Without timely and effective treatment, structural retinal damage
      escalates to frank retinal necrosis, occlusion of retinal vasculature,
      and extension of infection beyond the globe.
    evidence:
    - reference: PMID:31424768
      reference_title: Bacterial Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        As inflammation intensifies, retinal necrosis, vascular occlusion,
        and panophthalmitis may ensue.
      explanation: >-
        Directly documents the escalating, tissue-destructive and
        globe-extending complications that follow unchecked intraocular
        inflammation.
- name: Retinal Necrosis, Vascular Occlusion, and Panophthalmitis
  role: consequence
  biological_scale: TISSUE
  description: >-
    Escalating, unchecked intraocular inflammation and direct microbial
    invasion produce retinal necrosis and occlusion of the retinal
    vasculature, and infection may extend beyond the globe into the orbital
    tissues as panophthalmitis. HPO has no term for panophthalmitis or for
    infection-associated retinal necrosis as distinct from the specific viral
    acute retinal necrosis syndrome (HP:6001370), so this node is not bound
    to a phenotype_term; the end-stage anatomical outcome is captured as the
    Phthisis Bulbi phenotype below.
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As inflammation intensifies, retinal necrosis, vascular occlusion, and
      panophthalmitis may ensue.
    explanation: >-
      Directly documents retinal necrosis, vascular occlusion, and
      panophthalmitis as sequential complications of intensifying intraocular
      inflammation.
  downstream:
  - target: Phthisis Bulbi and Loss of the Eye
    causal_link_type: DIRECT
    description: >-
      Progression of untreated retinal necrosis, vascular occlusion, and
      panophthalmitis leads to end-stage globe destruction.
    evidence:
    - reference: PMID:31424768
      reference_title: Bacterial Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Without timely intervention, permanent visual impairment, phthisis
        bulbi, or even loss of the eye may occur.
      explanation: >-
        States the end-stage anatomical outcomes of untreated intraocular
        infection and inflammation.
- name: Phthisis Bulbi and Loss of the Eye
  role: consequence
  biological_scale: TISSUE
  description: >-
    End-stage, irreversible shrinkage and disorganization of the globe
    (phthisis bulbi), or outright loss of the eye, represents the most severe
    anatomical outcome of untreated or inadequately treated endophthalmitis.
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Without timely intervention, permanent visual impairment, phthisis
      bulbi, or even loss of the eye may occur.
    explanation: >-
      Directly documents phthisis bulbi and loss of the eye as the end-stage
      anatomical outcomes of untreated endophthalmitis.
phenotypes:
- category: Clinical
  name: Decreased Vision
  subtype: Acute Postoperative
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "decreased vision (95%), red eye (80%), and eye pain (75%)"
    explanation: >-
      Reports decreased vision in 95% of acute postoperative endophthalmitis
      cases, within the VERY_FREQUENT (80-99%) band. The source sentence
      scopes this figure to acute postoperative disease specifically, hence
      the subtype tag.
  sequelae:
  - target: Phthisis Bulbi
    description: >-
      Untreated or inadequately treated progressive vision loss can
      culminate in phthisis bulbi, the end-stage anatomical outcome of
      endophthalmitis.
    evidence:
    - reference: PMID:31424768
      reference_title: Bacterial Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Without timely intervention, permanent visual impairment, phthisis
        bulbi, or even loss of the eye may occur.
      explanation: >-
        Directly links untreated visual impairment progression to phthisis
        bulbi as an end-stage outcome.
- category: Clinical
  name: Eye Pain
  subtype: Acute Postoperative
  phenotype_term:
    preferred_term: Ocular pain
    term:
      id: HP:0200026
      label: Ocular pain
  frequency: FREQUENT
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "decreased vision (95%), red eye (80%), and eye pain (75%)"
    explanation: >-
      Reports eye pain in 75% of acute postoperative endophthalmitis cases,
      within the FREQUENT (30-79%) band. The source sentence scopes this
      figure to acute postoperative disease specifically, hence the subtype
      tag.
- category: Clinical
  name: Hypopyon
  subtype: Acute Postoperative
  phenotype_term:
    preferred_term: Hypopyon
    term:
      id: HP:0031615
      label: Hypopyon
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a hypopyon is present in >80% of cases"
    explanation: >-
      Reports hypopyon in over 80% of acute postoperative endophthalmitis
      cases, within the VERY_FREQUENT (80-99%) band. The source sentence
      scopes this figure to acute postoperative disease specifically, hence
      the subtype tag.
- category: Clinical
  name: Vitritis
  phenotype_term:
    preferred_term: Vitritis
    term:
      id: HP:0011531
      label: Vitritis
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On examination, clinicians may observe conjunctival injection,
      corneal edema, anterior chamber cells and flare, hypopyon, vitritis,
      and reduced fundus visibility.
    explanation: Documents vitritis as a characteristic examination finding.
- category: Clinical
  name: Conjunctival Injection
  subtype: Acute Postoperative
  phenotype_term:
    preferred_term: Conjunctival hyperemia
    term:
      id: HP:0030953
      label: Conjunctival hyperemia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "decreased vision (95%), red eye (80%), and eye pain (75%)"
    explanation: >-
      Reports red eye (conjunctival injection) in 80% of acute postoperative
      endophthalmitis cases, within the VERY_FREQUENT (80-99%) band. The
      source sentence scopes this figure to acute postoperative disease
      specifically, hence the subtype tag.
- category: Clinical
  name: Corneal Edema
  phenotype_term:
    preferred_term: Corneal edema
    term:
      id: HP:0012040
      label: Corneal stromal edema
  notes: >-
    The cited source reports generic "corneal edema" without specifying the
    corneal layer involved; HP:0012040 (Corneal stromal edema) is the closest
    available HPO term, but is narrower than the source claim (HPO also has
    HP:6001182 Corneal epithelial edema, and no unqualified "corneal edema"
    parent term). Binding to the stromal-specific term is a known
    over-specification, kept because HPO offers no generic alternative.
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On examination, clinicians may observe conjunctival injection,
      corneal edema, anterior chamber cells and flare, hypopyon, vitritis,
      and reduced fundus visibility.
    explanation: Documents corneal edema as a characteristic examination finding.
- category: Clinical
  name: Photophobia
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Initial symptoms typically include ocular pain, decreased vision,
      redness, photophobia, and floaters.
    explanation: Documents photophobia as an initial presenting symptom.
- category: Clinical
  name: Vitreous Floaters
  phenotype_term:
    preferred_term: Vitreous floaters
    term:
      id: HP:0100832
      label: Vitreous floaters
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Initial symptoms typically include ocular pain, decreased vision,
      redness, photophobia, and floaters.
    explanation: Documents floaters as an initial presenting symptom.
- category: Clinical
  name: Phthisis Bulbi
  phenotype_term:
    preferred_term: Phthisis bulbi
    term:
      id: HP:0000667
      label: Phthisis bulbi
  evidence:
  - reference: PMID:31424768
    reference_title: Bacterial Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Without timely intervention, permanent visual impairment, phthisis
      bulbi, or even loss of the eye may occur.
    explanation: >-
      Documents phthisis bulbi as an end-stage anatomical outcome of
      untreated endophthalmitis.
infectious_agent:
- name: Coagulase-Negative Staphylococci
  infectious_agent_term:
    preferred_term: Staphylococcus epidermidis
    term:
      id: NCBITaxon:1282
      label: Staphylococcus epidermidis
  description: >-
    The leading cause of acute postoperative endophthalmitis, introduced from
    the patient's own periocular flora at the time of intraocular surgery,
    and the leading cause of post-intravitreal-injection endophthalmitis.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Coagulase-negative staphylococci are the most common causes of
      post-cataract endophthalmitis
    explanation: Directly identifies coagulase-negative staphylococci as the predominant organism.
- name: Cutibacterium acnes
  infectious_agent_term:
    preferred_term: Cutibacterium acnes
    term:
      id: NCBITaxon:1747
      label: Cutibacterium acnes
  description: >-
    The classic cause of chronic (delayed-onset) postoperative
    endophthalmitis, sequestered within the lens capsular bag and producing
    an indolent course.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chronic post-cataract endophthalmitis is usually caused by
      Propionibacterium acnes
    explanation: >-
      Establishes Cutibacterium (Propionibacterium) acnes as the classic
      cause of chronic postoperative endophthalmitis.
- name: Bacillus cereus
  infectious_agent_term:
    preferred_term: Bacillus cereus
    term:
      id: NCBITaxon:1396
      label: Bacillus cereus
  description: >-
    A major and especially virulent cause of post-traumatic endophthalmitis,
    typically introduced via soil- or organic-material-contaminated
    penetrating injury.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bacillus cereus is a major pathogen in post-traumatic endophthalmitis,
      and causes a fulminant infection with very poor visual outcome
    explanation: Establishes Bacillus cereus as the characteristic post-traumatic pathogen.
- name: Streptococcus pneumoniae
  infectious_agent_term:
    preferred_term: Streptococcus pneumoniae
    term:
      id: NCBITaxon:1313
      label: Streptococcus pneumoniae
  description: >-
    A leading cause of bleb-associated endophthalmitis, entering via the
    thin, avascular filtering bleb.
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Streptococci, including Streptococcus pneumoniae, cause 50% of cases."
    explanation: Identifies Streptococcus pneumoniae as a leading bleb-associated pathogen.
biochemical:
- name: Vitreous Pro-Inflammatory Cytokine Elevation
  presence: INCREASED
  biomarker_term:
    preferred_term: Cytokine
    term:
      id: NCIT:C20464
      label: Cytokine
  context: >-
    Elevated vitreous levels of multiple pro-inflammatory cytokines and
    chemokines correlate with disease severity in culture-positive infectious
    endophthalmitis.
  readouts:
  - target: Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation
    relationship: READOUT_OF
    direction: POSITIVE
    evidence:
    - reference: PMID:30296277
      reference_title: >-
        Elevated cytokine levels in vitreous as biomarkers of disease
        severity in infectious endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Our results demonstrated elevated expression of 16 mediators such as
        GCSF, GRO, IFN-γ, IL-1α, IL-1β, IL-1 RA, IL-6, IL-8, IP-10, MCP-1,
        MCP-3, MIP-1α, IL-1β, TGF-α, TNF-α in patients with culture positive
        endophthalmitis.
      explanation: >-
        Directly reports the vitreous cytokine/chemokine elevation this
        biomarker readout links to the neutrophil- and cytokine-driven
        inflammation pathophysiology node.
  evidence:
  - reference: PMID:30296277
    reference_title: >-
      Elevated cytokine levels in vitreous as biomarkers of disease severity
      in infectious endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results demonstrated elevated expression of 16 mediators such as
      GCSF, GRO, IFN-γ, IL-1α, IL-1β, IL-1 RA, IL-6, IL-8, IP-10, MCP-1,
      MCP-3, MIP-1α, IL-1β, TGF-α, TNF-α in patients with culture positive
      endophthalmitis.
    explanation: >-
      Human vitreous-sample study demonstrating pro-inflammatory
      cytokine/chemokine elevation as a disease-severity biomarker in
      infectious endophthalmitis.
diagnosis:
- name: Intraocular Fluid Culture
  description: >-
    Endophthalmitis is a clinical diagnosis supported by microbiological
    culture of intraocular fluid (vitreous humor via vitrectomy or needle
    aspirate, or aqueous humor via needle aspirate). A negative culture
    occurs in a substantial minority of cases and does not exclude the
    diagnosis; the principal differential diagnosis is sterile intraocular
    inflammation (e.g. a postoperative reaction or toxic anterior segment
    syndrome).
  diagnosis_term:
    preferred_term: microbial culture procedure
    term:
      id: NCIT:C25300
      label: Microbial Culture Procedure
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Endophthalmitis is a clinical diagnosis, supported by culture of
      intra-ocular fluids, although a negative culture occurs in 30% of
      cases. The differential diagnosis is sterile intra-ocular inflammation.
    explanation: >-
      Establishes endophthalmitis as a clinical diagnosis supported by
      intraocular fluid culture, quantifies the negative-culture rate, and
      names the principal differential diagnosis.
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vitreous cultures are more likely to be positive after vitrectomy than
      vitreous aspirate (90% vs. 75%); aqueous cultures are positive in 40%
    explanation: >-
      Quantifies culture yield by sampling method and fluid compartment
      (vitrectomy vs. vitreous aspirate vs. aqueous aspirate).
- name: Gram Stain of Intraocular Fluid
  description: >-
    Gram staining of the intraocular fluid sample obtained for culture
    provides rapid, though imperfectly sensitive, identification of the
    infecting organism class pending culture results.
  diagnosis_term:
    preferred_term: Gram staining method
    term:
      id: NCIT:C23014
      label: Gram Staining Method
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gram stains are positive in 40–50% of cases."
    explanation: Quantifies the diagnostic yield of Gram staining of intraocular fluid.
treatments:
- name: Intravitreal Vancomycin
  description: >-
    Empirical intravitreal antibiotic covering gram-positive organisms
    (including coagulase-negative staphylococci), the predominant pathogens
    in postoperative endophthalmitis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vancomycin
      term:
        id: CHEBI:28001
        label: vancomycin
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intravitreal vancomycin 1 mg/0.1 mL normal saline plus either
      ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL
    explanation: Documents intravitreal vancomycin as first-line empirical broad-spectrum therapy.
  target_mechanisms:
  - target: Bacterial Peptidoglycan Precursor and Lipid II Synthesis (Vancomycin Target)
    treatment_effect: INHIBITS
    description: >-
      Vancomycin sequesters the D-Ala-D-Ala terminus of the lipid II
      peptidoglycan precursor, blocking cell-wall synthesis in the
      predominantly gram-positive organisms causing endophthalmitis.
    evidence:
    - reference: PMID:23438028
      reference_title: Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        intravitreal vancomycin 1 mg/0.1 mL normal saline plus either
        ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL
      explanation: Documents intravitreal vancomycin as first-line empirical therapy.
- name: Intravitreal Ceftazidime
  description: >-
    Empirical intravitreal antibiotic covering gram-negative organisms,
    combined with intravitreal vancomycin for broad-spectrum coverage pending
    culture results.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ceftazidime
      term:
        id: CHEBI:3508
        label: ceftazidime
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      intravitreal vancomycin 1 mg/0.1 mL normal saline plus either
      ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL
    explanation: Documents intravitreal ceftazidime as first-line empirical broad-spectrum therapy.
  target_mechanisms:
  - target: Bacterial Peptidoglycan Cross-Linking by Penicillin-Binding Proteins (Beta-Lactam Target)
    treatment_effect: INHIBITS
    description: >-
      Ceftazidime acylates the penicillin-binding protein active site,
      blocking peptidoglycan cross-linking to provide gram-negative and
      additional gram-positive coverage.
    evidence:
    - reference: PMID:23438028
      reference_title: Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        intravitreal vancomycin 1 mg/0.1 mL normal saline plus either
        ceftazidime 2.25 mg/0.1 mL or amikacin 0.4 mg/0.1 mL
      explanation: Documents intravitreal ceftazidime as first-line empirical therapy.
- name: Intravitreal Amikacin
  description: >-
    Alternative empirical intravitreal antibiotic for gram-negative
    coverage when ceftazidime is not used; repeated injection is avoided
    owing to concerns about retinal toxicity.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amikacin
      term:
        id: CHEBI:2637
        label: amikacin
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Repeated injections of amikacin are avoided, owing to concerns
      about retinal toxicity.
    explanation: >-
      Documents intravitreal amikacin as an empirical alternative to
      ceftazidime, with a dose-limiting retinal-toxicity caveat.
  target_mechanisms:
  - target: Bacterial mRNA Translation by the Ribosome (Aminoglycoside Target)
    treatment_effect: INHIBITS
    description: >-
      Amikacin binds the bacterial 30S ribosomal subunit, causing
      translational misreading and bactericidal effects in gram-negative
      organisms.
    evidence:
    - reference: PMID:23438028
      reference_title: Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Repeated injections of amikacin are avoided, owing to concerns
        about retinal toxicity.
      explanation: >-
        Documents intravitreal amikacin as an empirical alternative and
        notes its dose-limiting retinal toxicity.
- name: Intravitreal Corticosteroid
  description: >-
    Adjunctive intravitreal corticosteroid (dexamethasone) investigated
    alongside intravitreal antibiotics to target the neutrophil- and
    cytokine-driven retinal toxicity that can persist independently of
    antimicrobial killing. Evidence for benefit is low-certainty: a Cochrane
    review found current evidence on adjunctive steroid therapy versus
    antibiotics alone to be inadequate, though a combined analysis of two
    small trials suggested a higher probability of a good visual outcome at
    three months with adjunctive dexamethasone.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dexamethasone
      term:
        id: CHEBI:41879
        label: dexamethasone
  evidence:
  - reference: PMID:28225198
    reference_title: >-
      Adjunctive steroid therapy versus antibiotics alone for acute
      endophthalmitis after intraocular procedure.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Current evidence on the effectiveness of adjunctive steroid therapy
      versus antibiotics alone in the management of acute endophthalmitis
      after intraocular surgery is inadequate.
    explanation: >-
      Cochrane review's own authors' conclusion, quoted to keep the
      treatment entry honest about the limited certainty of current
      evidence for this adjunctive therapy.
  target_mechanisms:
  - target: Neutrophil- and Cytokine-Mediated Retinal Toxicity
    treatment_effect: INHIBITS
    description: >-
      Intravitreal dexamethasone is intended to suppress neutrophil- and
      cytokine-driven inflammatory injury to the retina independently of
      antimicrobial action against the causative organism.
    evidence:
    - reference: PMID:28225198
      reference_title: >-
        Adjunctive steroid therapy versus antibiotics alone for acute
        endophthalmitis after intraocular procedure.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Low-certainty evidence from two studies showed that a higher
        proportion of participants who received adjunctive dexamethasone
        had a good visual outcome (Snellen visual acuity 6/6 to 6/18) at
        three months compared with those in the antibiotics-alone group (RR
        1.95, 95% CI 1.05 to 3.60; 60 participants).
      explanation: >-
        Cochrane systematic review reporting low-certainty evidence of
        visual-outcome benefit from adjunctive intravitreal dexamethasone;
        supports the mechanistic rationale but the review's overall
        conclusion (inadequate evidence) is captured in the treatment
        description rather than overstated here.
- name: Pars Plana Vitrectomy
  description: >-
    Surgical removal of infected, inflamed vitreous, indicated for eyes
    with the most severe vision loss at presentation.
  treatment_term:
    preferred_term: Vitrectomy
    term:
      id: NCIT:C50837
      label: Vitrectomy
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vitrectomy decreased the rate of severe vision loss from 47% (tap
      group) to 20% (vitrectomy group) in patients who presented with the
      worst vision (light perception only).
    explanation: >-
      Endophthalmitis Vitrectomy Study finding, as reported in this review,
      establishing the clinical benefit of vitrectomy in the most severely
      affected eyes.
  target_mechanisms:
  - target: Intravitreal Microbial Proliferation
    treatment_effect: INHIBITS
    description: >-
      Vitrectomy surgically debrides the infected vitreous humor, physically
      removing the microbial and inflammatory-mediator reservoir, similar to
      draining an abscess.
    evidence:
    - reference: PMID:23438028
      reference_title: Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Vitrectomy decreased the rate of severe vision loss from 47% (tap
        group) to 20% (vitrectomy group) in patients who presented with the
        worst vision (light perception only).
      explanation: >-
        Reports the Endophthalmitis Vitrectomy Study finding that
        vitrectomy reduces severe vision loss in the most severely affected
        eyes.
- name: Systemic Antibiotic Therapy for Endogenous and Fungal Disease
  description: >-
    Systemic antimicrobial therapy directed at the underlying source of
    bacteremia or fungemia. Required in endogenous endophthalmitis (which is
    seeded hematogenously from an extraocular source) and used adjunctively
    in exogenous fungal endophthalmitis; intravitreal antibiotics remain
    necessary regardless, since systemic therapy alone does not adequately
    treat the intraocular infection.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:23438028
    reference_title: Endophthalmitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Systemic antibiotics are necessary to treat the underlying infection in
      endogenous endophthalmitis, and as adjunctive therapy in exogenous
      fungal endophthalmitis.
    explanation: >-
      States the indication for systemic (as opposed to intravitreal-only)
      antimicrobial therapy in endogenous and exogenous fungal disease.
  target_mechanisms:
  - target: Intravitreal Microbial Proliferation
    treatment_effect: INHIBITS
    description: >-
      Eliminating the extraocular bacteremic or fungemic source reduces
      continued hematogenous seeding of the vitreous cavity in endogenous
      disease, complementing intravitreal antibiotics, which act on the
      organisms already present intraocularly; systemic therapy alone does
      not effectively treat the established intraocular infection.
    evidence:
    - reference: PMID:23438028
      reference_title: Endophthalmitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Treatment of the underlying source of bacteraemia with systemic
        antibiotics is necessary, but this will not effectively treat the
        endophthalmitis: intravitreal antibiotics and, usually, a vitrectomy
        are necessary.
      explanation: >-
        Documents that systemic antibiotics treat the bacteremic source of
        continued seeding while intravitreal antibiotics act on the
        established intraocular infection itself.
clinical_trials:
- name: NCT00000130
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Randomized controlled trial (the Endophthalmitis Vitrectomy Study, EVS)
    establishing the role of initial pars plana vitrectomy, and of
    intravenous antibiotics, in the management of postoperative bacterial
    endophthalmitis. Underpins the vitrectomy indication and outcome data
    already cited in this entry's treatments and pathophysiology from
    PMID:23438028's summary of the trial's results.
  target_phenotypes:
  - preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: clinicaltrials:NCT00000130
    reference_title: Endophthalmitis Vitrectomy Study (EVS)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To determine the role of initial pars plana vitrectomy in the
      management of postoperative bacterial endophthalmitis.
    explanation: >-
      Registry record of the EVS trial's stated objective, establishing the
      trial identity underpinning the already-cited vitrectomy indication.
animal_models:
- name: Mouse TLR4-dependent retinal inflammatory response in Bacillus cereus endophthalmitis
  species: Mouse
  genotype: C57BL/6J (wild-type); TLR4-deficient comparator
  publication: PMID:29661181
  modeled_mechanisms:
  - target: Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Intravitreal Bacillus cereus challenge in mice reproduces
      TLR4-dependent upregulation of neutrophil-recruiting chemokines in the
      retina, recapitulating the innate-immune amplification arm of this
      node.
    limitations: >-
      Bacillus cereus endophthalmitis is a single, particularly virulent
      post-traumatic pathogen; the murine retinal chemokine response may not
      generalize to the coagulase-negative staphylococcal and streptococcal
      infections that predominate in postoperative and bleb-associated
      human disease.
    readouts:
    - name: Retinal chemokine gene expression
      target: Neutrophil Recruitment and Cytokine-Driven Intraocular Inflammation
      direction: INCREASED
      interpretation: >-
        Structural/molecular correlate of neutrophil-recruiting chemokine
        upregulation in this model.
      evidence:
      - reference: PMID:29661181
        reference_title: >-
          TLR4 modulates inflammatory gene targets in the retina during
          Bacillus cereus endophthalmitis.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Genes related to acute inflammation and inflammatory cell
          recruitment including CXCL1 (KC), CXCL2 (MIP2-α), CXCL10 (IP-10),
          CCL2 (MCP1), and CCL3 (MIP1-α)) were significantly upregulated
          5-fold or greater in C57BL/6 J retinas.
        explanation: >-
          Reports the quantitative retinal chemokine upregulation measured
          in this model.
    evidence:
    - reference: PMID:29661181
      reference_title: >-
        TLR4 modulates inflammatory gene targets in the retina during
        Bacillus cereus endophthalmitis.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Genes related to acute inflammation and inflammatory cell
        recruitment including CXCL1 (KC), CXCL2 (MIP2-α), CXCL10 (IP-10),
        CCL2 (MCP1), and CCL3 (MIP1-α)) were significantly upregulated
        5-fold or greater in C57BL/6 J retinas.
      explanation: >-
        Supports treating this model as informative for the neutrophil- and
        cytokine-driven inflammation node.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0017202
      label: acute endophthalmitis
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0017202 (acute endophthalmitis) is a narrower, temporal-onset
      concept subsumed by this entry's broader MONDO:0016047 (endophthalmitis)
      disease_term; too broad an axis (cutting across all routes of entry) to
      bind as a route-of-entry subtype_term, so it is captured here instead.
  - term:
      id: MONDO:0017203
      label: chronic endophthalmitis
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0017203 (chronic endophthalmitis) is a narrower, temporal-onset
      concept subsumed by this entry's broader MONDO:0016047 (endophthalmitis)
      disease_term; too broad an axis (cutting across all routes of entry) to
      bind as a route-of-entry subtype_term, so it is captured here instead.
  - term:
      id: MONDO:0004863
      label: purulent endophthalmitis
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0004863 (purulent endophthalmitis) is a narrower, suppurative-type
      concept subsumed by this entry's broader MONDO:0016047 (endophthalmitis)
      disease_term; too broad an axis to bind as a route-of-entry subtype_term,
      so it is captured here instead.
datasets: []
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 34 citations 2026-08-26T16:44:08.705735

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Endophthalmitis
  • MONDO ID: (if available)
  • Category: Infectious Disease

Research Objectives

Please provide a comprehensive research report on Endophthalmitis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Endophthalmitis: comprehensive disease-characteristics report

Executive summary

Endophthalmitis is a sight-threatening inflammatory syndrome caused most often by microbial infection of the aqueous, vitreous, retina, or adjacent intraocular tissues. Exogenous endophthalmitis follows surgery, intravitreal injection, penetrating trauma, keratitis, or filtering-bleb infection; endogenous endophthalmitis results from hematogenous seeding during bacteremia or fungemia. It is an ophthalmic emergency because pathogen proliferation, toxins, and an intense host inflammatory response can destroy retinal architecture within hours to days.

Modern series remain dominated by exogenous disease and Gram-positive organisms, especially coagulase-negative staphylococci. In an Australian 18-year cohort, 87.1% of cases were exogenous, post-cataract and post-injection cases each represented approximately 38%, organisms were recovered in 56%, and 52.5% of treated eyes improved visually. A German 2019–2023 series identified a pathogen in 58.7%; Staphylococcus epidermidis represented 58.1% of identified organisms. These figures are center- and procedure-dependent rather than population prevalence estimates. (englisch2026microbiologicaletiologyof pages 1-2, maher2026epidemiologymicrobiologymanagement pages 1-2, maher2026epidemiologymicrobiologymanagement pages 2-5)

The disease is not a Mendelian disorder: no causal germline gene, inheritance pattern, disease-defining variant, or routine genetic test is established. Recent mechanistic research instead concerns host-response genes and pathways—AMPKα1, NLRP3, cytokine signaling, macrophage polarization, and fungal-response transcriptomes—which may eventually support host-directed adjuncts but are not current clinical genetic biomarkers. (singh2024myeloidcellspecificdeletion pages 1-6, khapuinamai2024unveilingtheinnate pages 1-2)

1. Disease information

Definition and classification

Infectious endophthalmitis is microbial invasion of intraocular fluids or tissues producing severe inflammation. Panophthalmitis denotes extension through all ocular coats and often periocular tissue. Classification is clinically useful along four axes:

  1. Route: exogenous versus endogenous.
  2. Setting: postoperative, post-intravitreal injection, post-traumatic/foreign body, keratitis-associated, bleb-associated, or hematogenous.
  3. Timing: acute—usually days—or delayed/chronic, often weeks to months.
  4. Organism: bacterial, fungal, or rarely parasitic.

Endogenous endophthalmitis accounts for approximately 2–8% in reviews, although referral cohorts vary; recent series reported 7.9–12.9%. It is defined by bloodstream dissemination without preceding direct ocular inoculation. (alshehri2024endogenousendophthalmitisassociated pages 1-2, englisch2026microbiologicaletiologyof pages 1-2, maher2026epidemiologymicrobiologymanagement pages 1-2)

Identifiers and synonyms

  • Preferred name: Endophthalmitis.
  • Synonyms: infectious endophthalmitis, purulent endophthalmitis, intraocular infection; subtype terms include postoperative, post-injection, post-traumatic, endogenous, metastatic, bacterial, and fungal endophthalmitis.
  • ICD-10-CM: H44.0, purulent endophthalmitis; H44.1, other endophthalmitis. More specific child codes are jurisdiction/version dependent.
  • MeSH: Endophthalmitis.
  • MONDO: a MONDO concept exists for endophthalmitis, but the exact identifier should be verified against the current MONDO release before database ingestion rather than inferred here.
  • OMIM/Orphanet: not generally applicable as a primary inherited or rare Mendelian disease entity.
  • ICD-11: use the current browser’s endophthalmitis concept under disorders of the eye; release-specific code verification is required.

The evidence summarized here is predominantly aggregated disease-level information from cohorts, reviews, clinical studies, and model systems. Individual case reports are used only to illustrate rare organisms or presentations; it is not an EHR-derived patient profile.

2. Etiology, risk, and protective factors

Causal factors and infectious agents

Exogenous inoculation: Cataract surgery and intravitreal injection are now major causes in high-income settings. Other routes include pars plana vitrectomy, glaucoma surgery, penetrating trauma, retained intraocular foreign body, corneal ulcer, and infected filtering bleb. In a German series of 126 cases, antecedents were injection in 55.6%, cataract surgery in 23.8%, vitrectomy in 5.6%, and glaucoma surgery in 4.8%. (englisch2026microbiologicaletiologyof pages 1-2)

Endogenous seeding: Bloodstream organisms cross the blood–ocular barriers during bacteremia or fungemia. Common systemic sources include endocarditis, liver abscess, urinary infection, indwelling vascular access, gastrointestinal or hepatobiliary infection, and injection-drug use. COVID-era reports suggested increased fungal endogenous disease in critically ill, immunosuppressed patients, particularly involving Candida and Aspergillus. (alshehri2024endogenousendophthalmitisassociated pages 1-2, shah2025riskfactorsfor pages 1-2)

Organisms: Exogenous disease is usually Gram-positive: coagulase-negative staphylococci, S. aureus, streptococci, Enterococcus, and delayed Cutibacterium acnes. Virulent Gram-negative organisms include Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Trauma—especially soil-contaminated injury—is associated with Bacillus cereus. Endogenous fungi are commonly Candida or Aspergillus; rare molds can produce relapsing infection. In the German series, all Gram-positive isolates were vancomycin susceptible, but this should not substitute for local surveillance. (englisch2026microbiologicaletiologyof pages 1-2, saeed2024auniquecase pages 1-3, braga2024endogenousendophthalmitisdue pages 1-2)

Risk factors

  • Procedural: wound leak or poor wound construction, posterior-capsule rupture/vitreous loss, prolonged or complicated surgery, contaminated instruments/medications, inadequate antisepsis, repeated intravitreal injections, and filtering blebs.
  • Traumatic: delayed wound closure, dirty rural injury, lens disruption, and retained IOFB. In 218 cases, IOFB independently predicted poor postoperative vision in traumatic disease (OR 2.215; p=0.016). A 2024 metallic-injury cohort found IOFB associated with faster onset, greater WBC/neutrophil/CRP responses, and poorer control (R=0.39; p<0.05). (li2025clinicalretrospectiveanalysis pages 1-2, wu2024systematicinflammatoryindicators pages 1-2)
  • Endogenous: diabetes, malignancy, neutropenia, HIV/AIDS, transplantation, systemic corticosteroids or other immunosuppression, recent major surgery, indwelling catheter, parenteral nutrition, intravenous drug use, and endocarditis. Among 769,472 inpatients with infective endocarditis, 2,248 had coded endogenous endophthalmitis; diabetes with complications conferred OR 2.043, alcohol-use disorder OR 1.795, and cirrhosis OR 1.452. (shah2025riskfactorsfor pages 1-2)
  • Age/sex/geography: Exogenous cohorts skew older because cataract surgery and anti-VEGF treatment increase with age. In one cohort, median age was 76.8 years for exogenous versus 60.5 for endogenous disease. Trauma cohorts are often predominantly working-age men; a 2024 metallic-injury study was 86.2% male. Organism distributions vary geographically—hypervirulent Klebsiella endogenous infection is especially important in East and Southeast Asia. (maher2026epidemiologymicrobiologymanagement pages 2-5, wu2024systematicinflammatoryindicators pages 1-2)

Protective factors and gene–environment interactions

Strongly supported protective interventions are procedural rather than genetic: povidone–iodine antisepsis, sterile technique, prompt wound repair/foreign-body removal, and intracameral antibiotic prophylaxis during cataract surgery where adopted. No validated protective germline variant or modifier allele is known. Apparent host-genetic effects such as myeloid AMPKα1 activity are preclinical mechanistic observations, not population susceptibility loci. Thus, “gene–environment interaction” is best conceptualized as host immune/metabolic state interacting with pathogen virulence and inoculation route, rather than a validated clinical G×E association. (singh2024myeloidcellspecificdeletion pages 1-6)

3. Phenotypes

Typical disease is unilateral after a local procedure or injury; endogenous disease can be bilateral. Severity and progression range from indolent chronic inflammation to fulminant retinal destruction.

  • Reduced or rapidly declining vision: core symptom, variable from mild blur to hand-motion/light-perception vision. Suggested HPO: decreased visual acuity; blindness. Presenting acuity is among the strongest outcome predictors. (nowosielski2026visualacuityinfluences pages 1-2, braga2024endogenousendophthalmitisdue pages 1-2)
  • Eye pain and photophobia: common but not universal; pain can be absent in indolent or immunocompromised disease. Suggested HPO: eye pain; photophobia. (saeed2024auniquecase pages 1-3, braga2024endogenousendophthalmitisdue pages 1-2)
  • Red eye/conjunctival injection and eyelid edema: inflammatory signs. Suggested HPO: conjunctival hyperemia; periorbital edema. (saeed2024auniquecase pages 1-3, krohn2024endogenousfungalendophthalmitis pages 1-2)
  • Anterior chamber cells/flare, fibrin, hypopyon: signs of severe anterior inflammation. Suggested HPO: anterior uveitis; hypopyon. The 2024 E. coli case had a 3+/4+ anterior chamber reaction. (braga2024endogenousendophthalmitisdue pages 1-2)
  • Vitritis/vitreous haze, absent red reflex, poor fundus view: defining posterior-segment manifestations. Suggested HPO: vitritis; vitreous opacity. The same E. coli case had 4+/4+ vitritis. (braga2024endogenousendophthalmitisdue pages 1-2)
  • Floaters: common early posterior symptom. Suggested HPO: vitreous floaters. (braga2024endogenousendophthalmitisdue pages 1-2)
  • Retinal/choroidal infiltrates or abscesses: particularly endogenous bacterial or fungal disease. Suggested HPO: chorioretinal inflammation; retinal lesion. A hypervirulent Klebsiella case showed retinochoroidal abscesses by ultrasonography. (saeed2024auniquecase pages 1-3)
  • Laboratory abnormalities: ocular-fluid Gram stain/culture/PCR positivity; endogenous cases may have positive blood cultures, leukocytosis, elevated CRP, or systemic organ infection. No single blood biomarker is diagnostic.

Onset: Acute postoperative/post-injection disease often develops within approximately 3–7 days; an 18-year cohort reported a median of 5 days after procedure, whereas trabeculectomy-associated cases presented at a median 28 days. Chronic C. acnes or fungal disease can evolve over weeks or recur months after treatment withdrawal. (maher2026epidemiologymicrobiologymanagement pages 2-5, krohn2024endogenousfungalendophthalmitis pages 1-2)

Quality of life: Permanent monocular or bilateral visual loss affects reading, driving, employment, mobility, falls risk, and independence. Eye pain, repeated injections/surgery, prolonged antifungal treatment, and fear of losing the fellow eye add substantial burden. Endophthalmitis-specific EQ-5D/SF-36 reference values are limited; visual acuity and vision-related instruments such as NEI-VFQ are more disease-proximal.

4. Genetic and molecular information

No established causal genes, pathogenic germline variants, chromosomal abnormalities, inheritance pattern, penetrance, anticipation, founder effect, or carrier frequency applies to infectious endophthalmitis. ClinVar-style variant classification and routine WES/WGS, panel, CMA, karyotype, FISH, mtDNA, or repeat-expansion testing are therefore not indicated for diagnosis.

Host-response genes are research targets rather than disease-causing genes:

  • PRKAA1/AMPKα1: Myeloid-specific deletion in mice worsened S. aureus infection, elevated IL-1β, TNF-α, IL-6 and CXCL2, shifted macrophages toward inflammatory M1 states, and impaired phagocytosis. Wild-type marrow transfer preserved retinal function. The abstract states that deletion “skewed macrophage polarization toward the inflammatory M1 phenotype and impaired the phagocytic clearance of S. aureus.” This is model-organism causality, not evidence for pathogenic human PRKAA1 variants. Published October 2024; DOI/URL: https://doi.org/10.4049/jimmunol.2400282. (singh2024myeloidcellspecificdeletion pages 1-6)
  • NLRP3/miR-223-3p: Emerging translational work links extracellular-vesicle miR-223-3p with NLRP3 inflammasome modulation; potential diagnostic or therapeutic use remains experimental.
  • Fungal-response genes: Murine Candida RNA sequencing highlighted CD3-associated signaling, CAMP, LCK, C-type lectin, NOD-like receptor, T-cell, and NK-cell pathways. These represent infection-induced expression changes rather than inherited pathogenic variants. (khapuinamai2024unveilingtheinnate pages 1-2)

No reproducible disease-specific epigenetic signature, somatic mutation, structural genomic lesion, or clinical pharmacogenomic algorithm is established.

5. Environmental and lifestyle information

Relevant non-genetic exposures are primarily iatrogenic or traumatic: intraocular surgery, repeated injection, penetrating metal/organic injury, soil contamination, contact with contaminated compounded products, and healthcare-associated bloodstream infection. Hot/humid environments and regional microbiology may alter organism distributions, but no universal environmental exposure–response estimate is available.

Smoking, diet, alcohol, and exercise are not established direct causes of exogenous disease. Alcohol-use disorder was associated with endogenous disease among endocarditis inpatients, plausibly through liver disease, immune dysfunction, and infection risk rather than a direct ocular toxic effect. Diabetes and immunosuppressive therapy are clinically important host-environment modifiers. (shah2025riskfactorsfor pages 1-2)

There is no contagious person-to-person ocular transmission in ordinary endophthalmitis. The underlying systemic infection may itself be transmissible depending on the organism, but endophthalmitis is generally a complication rather than an independently transmitted disease.

6. Mechanism and pathophysiology

Causal chain

  1. Upstream trigger: Direct inoculation breaches the cornea/sclera or introduces organisms during surgery/injection; alternatively, bloodstream organisms cross retinal/choroidal vascular barriers.
  2. Early microbial phase: Organisms proliferate in immune-privileged, nutrient-rich aqueous/vitreous. Capsules, adhesins, biofilm, proteases, cytolysins, and toxins influence virulence. Bacillus, streptococci, Pseudomonas, Klebsiella, and molds can cause especially rapid damage.
  3. Innate recognition: Retinal Müller glia, resident microglia/macrophages, vascular cells, and infiltrating myeloid cells detect pathogen-associated molecules through TLR, C-type lectin, and NOD-like receptor pathways.
  4. Inflammatory amplification: NF-κB/inflammasome signaling and cytokines/chemokines—including IL-1β, TNF-α, IL-6 and CXCL2—recruit neutrophils and monocytes. These cells clear organisms but release proteases, reactive oxygen species, and inflammatory mediators that damage the blood-retinal barrier and neurons.
  5. Downstream tissue injury: Vitreous opacification, fibrin, edema, photoreceptor/inner-retinal dysfunction, ischemia, necrosis, retinal detachment, and fibrosis/PVR produce vision loss. Delayed therapy allows both microbial burden and immunopathology to become irreversible. (singh2024myeloidcellspecificdeletion pages 1-6)

Suggested terms include GO: inflammatory response, response to bacterium/fungus, neutrophil migration, macrophage activation, phagocytosis, cytokine-mediated signaling, NOD-like receptor signaling, inflammasome complex assembly, reactive oxygen species metabolic process, and apoptotic process. Suggested CL terms: neutrophil, monocyte, macrophage, microglial cell, retinal Müller glial cell, T cell, NK cell, retinal ganglion cell, and photoreceptor cell.

Recent molecular profiling

A 2024 C57BL/6 murine Candida albicans study found 27,717 differentially expressed transcripts overall and 1,493 significant DEGs—924 upregulated and 569 downregulated. Upregulated pathways included T-cell signaling, NK-cell cytotoxicity, C-type lectin and NOD-like receptor signaling; MAPK, cAMP, and metabolic pathways were downregulated. The model used intravitreal Candida and sampled at 24 and 72 hours, so it depicts early experimental disease rather than the full human course. Published September 2024; DOI/URL: https://doi.org/10.1021/acsomega.4c05081. (khapuinamai2024unveilingtheinnate pages 1-2)

The 2024 AMPK study integrated retinal transcriptomic/metabolic findings implicating immune signaling, antimicrobial defense, ER stress, trafficking, NAD+ metabolism, and lipid biosynthesis. These data support immunometabolic regulation of resolution but do not yet justify AMPK-targeted human treatment. (singh2024myeloidcellspecificdeletion pages 1-6)

Human single-cell, spatial-transcriptomic, lipidomic, and validated multi-omic diagnostic signatures remain sparse. This is an important evidence gap.

7. Anatomical structures affected

The primary organ is the eye, especially:

  • Vitreous body and vitreous chamber—major inflammatory compartment.
  • Aqueous humor/anterior chamber—cells, flare, fibrin, and hypopyon.
  • Retina, retinal pigment epithelium, and choroid—neuronal injury, infiltrates, abscesses, ischemia, edema.
  • Ciliary body, lens capsule, and intraocular lens surfaces—potential microbial reservoirs in chronic disease.
  • Cornea and sclera—entry routes or contiguous sources; extensive infection may progress to panophthalmitis.
  • Optic nerve—secondary injury in destructive disease.

Suggested UBERON terms: eye, vitreous humor, anterior chamber of eyeball, retina, retinal pigment epithelium, choroid, ciliary body, lens, cornea, sclera, and optic nerve. Suggested GO cellular components include inflammasome complex, extracellular vesicle, lysosome/phagolysosome, plasma membrane, and extracellular space. Disease is usually unilateral after local inoculation but can be bilateral in endogenous fungemia.

A recurrent 2024 dematiaceous fungal case demonstrated persistent organisms at the ciliary processes and posterior lens surface, illustrating protected anatomical reservoirs. Despite local/systemic therapy, recurrence led to painful glaucoma and enucleation. Published June 2024; DOI/URL: https://doi.org/10.1186/s12348-024-00408-y. (krohn2024endogenousfungalendophthalmitis pages 1-2)

8. Temporal development

Acute bacterial disease generally progresses over hours to days. The key therapeutic window is before irreversible retinal damage: one 2024 trauma series found intervention within two hours of symptom exacerbation associated with fewer complications (AUC 0.708, 95% CI 0.547–0.838; p=0.047). This small retrospective result supports urgency but is not a universally validated cutoff. (wu2024systematicinflammatoryindicators pages 1-2)

A practical course is:

  • Early: pain/blur, anterior reaction, small retinal infiltrate or mild vitritis.
  • Intermediate: dense vitritis, hypopyon, marked acuity loss, retinal/choroidal lesions.
  • Advanced: no fundus view, retinal necrosis/ischemia or detachment, panophthalmitis.
  • Recovery/sequelae: clearing inflammation with variable visual recovery, or macular edema, epiretinal membrane, PVR, retinal detachment, glaucoma, hypotony, phthisis, or enucleation.

Fungal and C. acnes disease may be indolent or relapsing. The Cladophialophora case recurred three months after treatment discontinuations despite prolonged antifungals, illustrating that apparent remission may not equal eradication. (krohn2024endogenousfungalendophthalmitis pages 1-2)

9. Epidemiology, inheritance, and population

No universal prevalence per 100,000 is meaningful because endophthalmitis is usually reported per procedure or among bloodstream infections. Historical post-cataract rates were approximately 0.13–0.15%; contemporary rates are often lower with small-incision surgery, antisepsis, and intracameral prophylaxis. Post-injection risk in one Australian cohort was 0.035%, approximately 1 per 2,857 injections, with cumulative risk rising as injections accumulate. (maher2026epidemiologymicrobiologymanagement pages 8-9)

In 232 Australian cases from 2006–2024, exogenous disease accounted for 87.1%, endogenous 12.9%, and annual cases declined (slope −0.17/year; p=0.005), driven by declining post-cataract disease while injection-associated cases rose. Organisms were predominantly Gram-positive cocci. These are referral-center distributions, not national incidence estimates. (maher2026epidemiologymicrobiologymanagement pages 1-2, maher2026epidemiologymicrobiologymanagement pages 2-5)

Sex and age patterns reflect exposure: older adults dominate postoperative/injection disease, whereas traumatic cases often affect younger men. Endogenous disease varies with regional bloodstream pathogens; hypervirulent Klebsiella and diabetes are particularly relevant in Asian populations. There is no AD, AR, X-linked, mitochondrial, polygenic-inheritance, carrier, consanguinity, anticipation, or mosaicism framework for the disease.

10. Diagnostics

Emergency clinical work-up

Diagnosis is clinical and treatment should not await laboratory confirmation. Assess visual acuity, pupils, intraocular pressure, slit-lamp inflammation/hypopyon, wound/bleb/cornea, and dilated fundus. If media opacity prevents retinal examination, B-scan ultrasound evaluates vitreous echoes, membranes, retinal detachment, choroidal thickening, or abscess. OCT/OCTA can characterize macular or chorioretinal sequelae once imaging is possible. (saeed2024auniquecase pages 1-3)

Obtain aqueous and preferably vitreous samples for microscopy, aerobic/anaerobic bacterial and fungal culture, susceptibility testing, and targeted or broad-range PCR. In endogenous disease, obtain multiple blood cultures before systemic antimicrobials when feasible and investigate endocarditis, liver/renal/urinary infection, catheter infection, or other source.

Culture sensitivity is limited: positivity was 44.04% in a 218-case Chinese series and 53.2% in a German series; in the latter, overall organism detection was 58.7%, while PCR detected 43.5%. The authors concluded that no single method identified every infection, supporting combined culture and molecular testing. (englisch2026microbiologicaletiologyof pages 1-2, li2025clinicalretrospectiveanalysis pages 1-2)

Emerging diagnostics

Broad-range 16S/18S/ITS PCR and metagenomic next-generation sequencing can detect nonviable, unculturable, unexpected, or antibiotic-exposed organisms. A 2024 infectious-uveitis pilot tested aqueous from 20 eyes; MGS found candidate pathogens in seven and conventional ELISA/qPCR verified five. Its abstract states that MGS “cannot completely replace the traditional diagnostic techniques,” accurately reflecting current limitations: contamination, low biomass, background reads, cost, turnaround time, and uncertain causal interpretation. Molecular sequencing is therefore an adjunct, especially for culture-negative, atypical, fungal, or chronic cases, not a replacement for culture and susceptibility testing. (asao2025overviewofmicroorganisms pages 26-28)

Differential diagnosis

Rule out toxic anterior-segment syndrome—usually earlier, often painless, and initially anterior-predominant—sterile post-injection inflammation, severe noninfectious uveitis, retained lens material, lens-induced inflammation, suprachoroidal hemorrhage, retinal necrosis, intraocular foreign-body inflammation, and vitreoretinal lymphoma. Vitreoretinal lymphoma is especially important in chronic, steroid-responsive/recurrent “uveitis.”

No asymptomatic population screening or genetic testing is recommended. Targeted ophthalmic examination may be appropriate in candidemia or high-risk bacteremia according to local infectious-disease/ophthalmology guidance and symptoms.

11. Outcome and prognosis

Endophthalmitis rarely determines long-term survival directly, except as a marker of severe systemic sepsis; conventional 5- or 10-year survival measures are not useful. Ocular morbidity is substantial.

In the Australian cohort, 52.5% improved by at least one visual category. In the 218-case Chinese study, acuity >0.02 increased from 12.39% at admission to 27.98% at discharge (p<0.001). A later cohort reported improvement from median 2.3 logMAR at diagnosis to 1.0 at six months. (maher2026epidemiologymicrobiologymanagement pages 5-8, li2025clinicalretrospectiveanalysis pages 1-2, nowosielski2026visualacuityinfluences pages 1-2)

Poor prognostic factors include light-perception/no-light-perception presentation, treatment delay, virulent streptococci, Bacillus, Gram-negative rods or molds, endogenous route, corneal source, retinal/choroidal involvement, IOFB, retinal detachment, immunosuppression, and inadequate source control. Presenting visual acuity is consistently a major predictor. In one exogenous cohort, delayed surgery increased the re-intervention hazard (HR 5.7, 95% CI 2.9–11.1; p<0.001), although retrospective confounding limits causal interpretation. (nowosielski2026visualacuityinfluences pages 1-2)

Complications include macular edema, epiretinal membrane, retinal detachment/PVR, optic atrophy, secondary glaucoma, hypotony/phthisis, cataract, recurrent infection, evisceration/enucleation, and permanent blindness. Fungal cases may also reflect life-threatening disseminated infection. (krohn2024endogenousfungalendophthalmitis pages 1-2)

12. Treatment

Emergency algorithm

  1. Treat suspected infectious endophthalmitis as a same-day emergency.
  2. Obtain vitreous/aqueous samples without materially delaying treatment.
  3. Give empiric intravitreal vancomycin plus ceftazidime for broad Gram-positive and Gram-negative coverage; local protocols and allergy/resistance patterns govern alternatives.
  4. Consider early pars plana vitrectomy for light-perception vision, dense vitreous disease, severe/rapidly progressive infection, IOFB, retinal complications, fungal infection, inadequate response, or need for better diagnostic/source control.
  5. Add systemic antimicrobials for endogenous disease and eradicate the systemic source. Routine systemic antibiotics add limited value in uncomplicated acute post-cataract disease, consistent with landmark EVS evidence.
  6. Use cycloplegia, analgesia, careful pressure control, and topical corticosteroid only under antimicrobial coverage and specialist direction. The role of intravitreal corticosteroid remains controversial.

Intravitreal therapy was used in 97.3% and vitrectomy in 41.5% of the Australian cohort. The vitrectomy win ratio was 1.31 overall but 2.28 in the light-perception subgroup; neither estimate reached conventional significance in that retrospective analysis, but the direction aligns with the landmark Endophthalmitis Vitrectomy Study. (maher2026epidemiologymicrobiologymanagement pages 5-8, maher2026epidemiologymicrobiologymanagement pages 1-2)

Suggested NCIT terms: Intravitreal Injection; Vancomycin; Ceftazidime; Pars Plana Vitrectomy/Vitrectomy; Antibiotic Therapy; Antifungal Therapy; Cycloplegic Agent; Corticosteroid Therapy.

Organism-specific considerations

  • Bacteria: tailor to ocular-fluid susceptibilities; repeat intravitreal treatment or vitrectomy if worsening.
  • Yeasts: intravitreal amphotericin B or voriconazole plus systemic fluconazole/voriconazole when susceptible, with vitrectomy for significant vitritis.
  • Molds: intravitreal and systemic voriconazole are commonly used; amphotericin or other azoles depend on species/susceptibility. Surgical source control is frequently required.
  • Rare fungi: prolonged therapy and repeated sampling may be necessary. A 2024 Cladophialophora case required amphotericin, itraconazole, repeated intravitreal voriconazole, posaconazole, and isavuconazole yet ultimately underwent enucleation. (krohn2024endogenousfungalendophthalmitis pages 1-2)

There is no approved gene, cell, RNA, or immune-checkpoint therapy. AMPK activation, inflammasome modulation, EV-miRNA biomarkers, antimicrobial nanoparticles, and phage/host-directed approaches remain experimental.

Trials and implementation

Relevant ClinicalTrials.gov records found include the completed phase-3 EVS (NCT00000130), ESCRS cataract prophylaxis study (NCT00136344; approximately 35,000), intracameral moxifloxacin prevention trial (NCT02595359; phase 2, 1,000), early vitrectomy studies NCT04192994 and NCT05249413, recruiting nanopore-sequencing study NCT05372861, and recruiting vascular-change observational study NCT07175311. These records should be checked directly for current status and posted results before structured ingestion.

13. Prevention

Primary prevention: preoperative ocular-surface assessment; treatment of active lid/corneal infection when surgery is elective; povidone–iodine preparation of conjunctival sac and periocular skin; sterile lid speculum, instruments and medication handling; secure wounds; and intracameral antibiotic prophylaxis for cataract surgery where supported by policy. Intracameral agents prevent rather than treat infection; drug choice, formulation, dilution safety, allergy, and stewardship matter.

Injection prevention: povidone–iodine remains central; minimize talking or use masks according to protocol, avoid needle contact with lids/lashes, use sterile single-use equipment, and educate patients about pain, redness, or vision decline. Routine peri-injection topical antibiotics are generally not favored because they do not clearly reduce risk and select resistance.

Trauma prevention: occupational eye protection; urgent closure of open globe; prompt IOFB removal and antimicrobial prophylaxis based on injury contamination. The 2024 metallic-trauma data reinforce rapid escalation when symptoms worsen. (wu2024systematicinflammatoryindicators pages 1-2)

Secondary/tertiary prevention: rapid recognition, immediate intravitreal therapy, culture-guided adjustment, systemic-source control, serial retinal imaging, and management of retinal detachment, edema, glaucoma, and low-vision needs. No vaccine, genetic screening, carrier testing, prenatal testing, or population screening program applies.

14. Other species and natural disease

Naturally occurring endophthalmitis occurs in companion and production animals after trauma, surgery, corneal ulceration, or hematogenous infection. Reported host species include dog (Canis lupus familiaris, NCBI Taxon 9615), cat (Felis catus, 9685), horse (Equus caballus, 9796), cattle (Bos taurus, 9913), and birds. Organisms and anatomy overlap with humans, but exposure patterns, veterinary access, and likelihood of enucleation differ. Breed-specific Mendelian predisposition and VBO mappings are not established as general features.

The condition itself is not ordinarily zoonotic. Shared environmental organisms may infect different species, and animal-associated trauma could introduce pathogens, but cross-species transmission is not a defining mechanism.

15. Model organisms

Mouse: C57BL/6 intravitreal inoculation with S. aureus, Pseudomonas, Bacillus, Candida, or Aspergillus is the dominant mammalian model. It reproduces microbial growth, neutrophil influx, cytokine induction, retinal dysfunction, and histologic damage, and supports knockout, bone-marrow chimera, transcriptomic, metabolomic, and treatment experiments. The 2024 AMPKα1 model demonstrated myeloid-cell control of macrophage phenotype and bacterial clearance; the Candida model resolved early innate/adaptive transcriptional programs. (singh2024myeloidcellspecificdeletion pages 1-6, khapuinamai2024unveilingtheinnate pages 1-2)

Rabbit: Larger eyes facilitate surgery, pharmacokinetics, intravitreal dosing, implant testing, and serial sampling, although immunological reagents/genetic tools are less extensive than in mice.

Zebrafish (Danio rerio, NCBI Taxon 7955): Intravitreal S. aureus did not reproduce destructive murine/human disease. Fish maintained retinal architecture and rapidly cleared bacteria via retinal vessels/optic nerve with a monocyte/macrophage response. It is therefore a model of protective innate clearance rather than a faithful severe-endophthalmitis model.

In vitro/ex vivo: Retinal Müller glia, microglia/macrophages, retinal pigment epithelium, organotypic retinal explants, and ocular-fluid pathogen assays support receptor, cytokine, biofilm, toxicity, and antimicrobial studies. Human retinal organoids and eye-on-chip systems are promising but not yet validated replacements for in vivo disease.

Principal limitations are artificial high-dose intravitreal inoculation, compressed time course, species-specific immunity, lack of cataract hardware or human comorbidities, and imperfect modeling of vision. Model findings should be annotated as preclinical rather than human causal evidence.

Recent 2023–2024 research highlights and expert interpretation

  1. Immunometabolic regulation: The October 2024 AMPKα1 study gives causal model evidence that macrophage metabolism can determine bacterial clearance versus destructive inflammation. It identifies a plausible adjunctive-treatment direction, but human dosing and the risk of suppressing antimicrobial defense require study. (singh2024myeloidcellspecificdeletion pages 1-6)
  2. Fungal systems biology: The September 2024 Candida transcriptome demonstrated coordinated innate and adaptive activation rather than purely neutrophil-driven disease. The enormous DEG count and intravitreal challenge design demand cautious translation. (khapuinamai2024unveilingtheinnate pages 1-2)
  3. Precision microbiology: Molecular sequencing can rescue selected culture-negative diagnoses, but the most defensible current implementation is culture plus targeted PCR/mNGS—not sequencing alone—because only culture yields routine phenotypic susceptibility. (englisch2026microbiologicaletiologyof pages 1-2, asao2025overviewofmicroorganisms pages 26-28)
  4. Urgency in trauma: The December 2024 metallic-IOFB cohort links delayed treatment and systemic inflammatory patterns with difficult control. Its small sample supports, but does not independently establish, a universal two-hour threshold. (wu2024systematicinflammatoryindicators pages 1-2)
  5. Changing epidemiology: Better cataract prophylaxis has reduced post-cataract disease in some systems, while repeated anti-VEGF injections shift absolute case burden toward post-injection infection. Prevention programs should therefore monitor both procedure volume and infection per procedure. (maher2026epidemiologymicrobiologymanagement pages 8-9, maher2026epidemiologymicrobiologymanagement pages 2-5)

Selected exact abstract quotations

  • “Endogenous endophthalmitis (EE) is a rare but severe intraocular infection resulting from hematogenous dissemination of microorganisms.” Alshehri, September 2024; https://doi.org/10.7759/cureus.70523. (alshehri2024endogenousendophthalmitisassociated pages 1-2)
  • “Endophthalmitis is a severe form of purulent inflammation caused by the infection of the intraocular tissues or fluids.” Braga et al., March 2024; https://doi.org/10.5935/0004-2749.2023-0066. (braga2024endogenousendophthalmitisdue pages 1-2)
  • “The deletion of AMPKα1 in myeloid cells skewed macrophage polarization toward the inflammatory M1 phenotype and impaired the phagocytic clearance of S. aureus by macrophages.” Singh et al., October 2024; https://doi.org/10.4049/jimmunol.2400282. (singh2024myeloidcellspecificdeletion pages 1-6)
  • The rare-fungal report concluded that, “Despite early diagnosis and prolonged local and systemic antifungal therapy, it was not possible to achieve long-term control of the fungal infection.” Krohn et al., June 2024; https://doi.org/10.1186/s12348-024-00408-y. (krohn2024endogenousfungalendophthalmitis pages 1-2)

PMIDs were not consistently available in the retrieved full-text metadata; DOI URLs are therefore supplied and should be resolved against PubMed during final database curation.

Ontology-ready summary

The following table consolidates phenotype, anatomical, mechanistic, diagnostic, treatment, and model annotations. Exact ontology identifiers marked uncertain should be validated against current releases before production ingestion.

domain knowledge-base statement suggested ontology terms/IDs evidence type
Disease definition Endophthalmitis is a severe intraocular infection/inflammation involving ocular fluids and tissues; major clinical forms are exogenous (postoperative, post-injection, post-traumatic) and endogenous (hematogenous spread). (maher2026epidemiologymicrobiologymanagement pages 1-2, alshehri2024endogenousendophthalmitisassociated pages 1-2) MONDO: term-name-only suggestion endophthalmitis (exact MONDO ID uncertain); MeSH: Endophthalmitis (term-name-only); ICD-10: H44.0 Purulent endophthalmitis, H44.1 Other endophthalmitis Human clinical cohorts; systematic review
Resource provenance Most knowledge here is aggregated disease-level evidence from cohorts, systematic reviews, guidelines, and model-organism studies rather than individual-patient EHR alone. (maher2026epidemiologymicrobiologymanagement pages 5-8, alshehri2024endogenousendophthalmitisassociated pages 1-2, singh2024myeloidcellspecificdeletion pages 1-6) Evidence provenance annotation: aggregated disease-level resource Mixed evidence synthesis
Classification Exogenous disease predominates overall; endogenous disease is a minority but clinically important subtype. In a German state study, only 7.9% were endogenous; in an Australian cohort, 87.1% were exogenous. (englisch2026microbiologicaletiologyof pages 1-2, maher2026epidemiologymicrobiologymanagement pages 1-2) Disease subtypes: exogenous endophthalmitis (term-name-only), endogenous endophthalmitis (term-name-only) Human epidemiology
Disease timing Presentation is usually acute/subacute after ocular procedures; median time to presentation was 5 days post-procedure in one 18-year cohort. (maher2026epidemiologymicrobiologymanagement pages 2-5) HPO term-name-only suggestions: Acute onset, Abnormality of vision; temporal annotation: acute/subacute Human cohort
Phenotype Reduced visual acuity is a core presenting feature and major prognostic marker. (nowosielski2026visualacuityinfluences pages 1-2, braga2024endogenousendophthalmitisdue pages 1-2) HPO: Decreased visual acuity (exact ID not asserted) Human cohort; case report
Phenotype Ocular pain is common, especially in endogenous fungal or bacterial presentations. (saeed2024auniquecase pages 1-3, krohn2024endogenousfungalendophthalmitis pages 1-2) HPO term-name-only: Eye pain Human case reports
Phenotype Red eye/conjunctival injection is a typical inflammatory manifestation. (saeed2024auniquecase pages 1-3, krohn2024endogenousfungalendophthalmitis pages 1-2) HPO term-name-only: Red eye Human case reports
Phenotype Vitritis/vitreous opacity is a hallmark sign and often limits retinal visualization. (krohn2024endogenousfungalendophthalmitis pages 1-2, braga2024endogenousendophthalmitisdue pages 1-2) HPO term-name-only: Vitritis, Vitreous haze Human case reports
Phenotype Hypopyon/anterior chamber reaction occurs in severe bacterial cases. (saeed2024auniquecase pages 1-3, braga2024endogenousendophthalmitisdue pages 1-2) HPO term-name-only: Hypopyon, Anterior chamber inflammation Human case reports
Phenotype Floaters and photophobia may occur in endogenous disease. (braga2024endogenousendophthalmitisdue pages 1-2) HPO term-name-only: Floaters, Photophobia Human case report
Complications Severe outcomes include retinal damage, retinal detachment/PVR after surgery, secondary glaucoma, enucleation, and permanent vision loss. (krohn2024endogenousfungalendophthalmitis pages 1-2, nowosielski2026visualacuityinfluences pages 1-2) HPO term-name-only: Retinal detachment, Secondary glaucoma, Blindness Human case report; cohort
Anatomy Primary affected compartments are vitreous body and aqueous/anterior chamber, with spread to retina and choroid; fungal disease may persist at ciliary processes and posterior lens surface. (krohn2024endogenousfungalendophthalmitis pages 1-2, braga2024endogenousendophthalmitisdue pages 1-2) UBERON term-name-only: vitreous humor, anterior chamber of eyeball, retina, choroid, ciliary body, lens Human pathology/case reports
Localization Endogenous cases may show retinochoroidal abscess/chorioretinal involvement. (saeed2024auniquecase pages 1-3) UBERON/HPO term-name-only: retinochoroidal abscess, chorioretinal lesion Human imaging/case report
Etiology Exogenous causes include cataract surgery, intravitreal injection, vitrectomy, glaucoma surgery, and penetrating trauma/IOFB. (englisch2026microbiologicaletiologyof pages 1-2, wu2024systematicinflammatoryindicators pages 1-2) Exposure annotations: cataract surgery, intravitreal injection, penetrating eye injury, intraocular foreign body Human cohort
Etiology Endogenous disease results from hematogenous dissemination during systemic infection; associated settings include bacteremia, infective endocarditis, urinary tract infection, diabetes, immunosuppression, and indwelling catheters. (alshehri2024endogenousendophthalmitisassociated pages 1-2, shah2025riskfactorsfor pages 1-2, braga2024endogenousendophthalmitisdue pages 1-2) Disease/exposure term-name-only: bacteremia, infective endocarditis, urinary tract infection, immunosuppression, diabetes mellitus Systematic review; cohort; case report
Pathogens Gram-positive cocci predominate overall; Staphylococcus epidermidis is the most common organism in multiple cohorts. (englisch2026microbiologicaletiologyof pages 1-2, li2025clinicalretrospectiveanalysis pages 1-2) NCBI Taxonomy term-name-only: Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis Human microbiology cohorts
Pathogens Other important bacteria include streptococci, Pseudomonas aeruginosa, Escherichia coli, and hypervirulent Klebsiella pneumoniae. (maher2026epidemiologymicrobiologymanagement pages 5-8, saeed2024auniquecase pages 1-3, braga2024endogenousendophthalmitisdue pages 1-2) NCBI Taxonomy term-name-only: Streptococcus spp., Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae Human cohort; case reports
Pathogens Fungal causes include Candida albicans, Aspergillus spp., and rare dematiaceous fungi such as Cladophialophora devriesii; fungi are relatively more important in endogenous disease. (alshehri2024endogenousendophthalmitisassociated pages 1-2, krohn2024endogenousfungalendophthalmitis pages 1-2, englisch2026microbiologicaletiologyof pages 1-2) NCBI Taxonomy term-name-only: Candida albicans, Aspergillus spp., Cladophialophora devriesii Systematic review; case report; cohort
Epidemiology Post-cataract and post-injection disease are currently dominant exogenous forms; one Australian cohort found both accounted for 38.1% each among all cases. (maher2026epidemiologymicrobiologymanagement pages 2-5) Epidemiology annotation only Human cohort
Epidemiology Post-injection endophthalmitis risk in one anti-VEGF era cohort was approximately 0.035% (about 1 in 2,857 injections). (maher2026epidemiologymicrobiologymanagement pages 8-9) Epidemiology annotation only Human cohort
Risk factor Metallic intraocular foreign body correlates with faster symptom onset and poorer control after vitrectomy. (wu2024systematicinflammatoryindicators pages 1-2, li2025clinicalretrospectiveanalysis pages 1-2) Exposure term-name-only: intraocular foreign body Human cohort
Risk factor In infective endocarditis patients, diabetes, alcohol use disorder, cirrhosis, and older age increased endogenous endophthalmitis risk. (shah2025riskfactorsfor pages 1-2) Disease/exposure term-name-only: diabetes mellitus, alcohol use disorder, cirrhosis, advanced age Human database study
Protective factor In a national post-injection study, non-smoking was protective. (maher2026epidemiologymicrobiologymanagement pages 8-9) Exposure term-name-only: non-smoker status Human epidemiology
Immune mechanism Disease pathogenesis involves rapid innate immune activation with neutrophil infiltration, inflammatory cytokines, and retinal tissue injury. (singh2024myeloidcellspecificdeletion pages 1-6, khapuinamai2024unveilingtheinnate pages 1-2) GO term-name-only: neutrophil migration, inflammatory response, cytokine-mediated signaling pathway; CL term-name-only: neutrophil Murine model; translational
Immune mechanism Key inflammatory mediators elevated in bacterial endophthalmitis include IL-1β, TNF-α, IL-6, and CXCL2. (singh2024myeloidcellspecificdeletion pages 1-6) GO term-name-only: interleukin-1 production, tumor necrosis factor production, interleukin-6 production, chemokine production Murine model
Immune mechanism Macrophage phenotype influences outcome; myeloid AMPKα1 supports infection resolution, whereas deletion skews toward inflammatory M1 macrophages and impairs phagocytic clearance. (singh2024myeloidcellspecificdeletion pages 1-6) GO term-name-only: macrophage activation, phagocytosis, response to bacterium; CL term-name-only: macrophage, monocyte Murine model
Immune mechanism Fungal endophthalmitis transcriptomics showed enriched T-cell signaling, NK-cell mediated cytotoxicity, C-type lectin receptor signaling, and NOD-like receptor signaling. (khapuinamai2024unveilingtheinnate pages 1-2) GO/Pathway term-name-only: T cell activation, natural killer cell mediated immunity, pattern recognition receptor signaling pathway, NOD-like receptor signaling pathway Murine transcriptomics
Molecular profiling In murine Candida albicans endophthalmitis, 1,493 significant DEGs were reported (924 upregulated, 569 downregulated). (khapuinamai2024unveilingtheinnate pages 1-2) Omics annotation only Murine RNA-seq
Molecular profiling Extracellular-vesicle miR-223-3p is linked to modulation of the NLRP3 inflammasome and may have biomarker potential in culture-negative bacterial disease. (singh2024myeloidcellspecificdeletion pages 1-6) GO term-name-only: inflammasome complex assembly; molecular entities: miR-223-3p, NLRP3 Murine + human vitreous translational study
Cell types Major involved cells include neutrophils, monocytes/macrophages, retinal immune cells, T cells, and NK cells. (singh2024myeloidcellspecificdeletion pages 1-6, khapuinamai2024unveilingtheinnate pages 1-2) CL term-name-only: neutrophil, monocyte, macrophage, T cell, natural killer cell, retinal Müller glial cell (supportive literature context) Murine model
Diagnostics Core microbiology remains vitreous/aqueous sampling with Gram stain/culture plus molecular testing; no single method detects all cases. (englisch2026microbiologicaletiologyof pages 1-2) Diagnostic procedure term-name-only: vitreous tap, aqueous tap, microbial culture, broad-range PCR Human cohort
Diagnostics Culture positivity is incomplete: 58.7% in one German series and 44.0% in one Chinese series. (englisch2026microbiologicaletiologyof pages 1-2, li2025clinicalretrospectiveanalysis pages 1-2) Laboratory finding annotation only Human cohorts
Diagnostics Metagenomic sequencing is an emerging adjunct for infectious uveitis/endophthalmitis workups, especially when culture/PCR are negative or limited. (asao2025overviewofmicroorganisms pages 26-28) Diagnostic procedure term-name-only: metagenomic sequencing, mNGS Review/technology assessment
Imaging B-scan ultrasonography can identify vitritis and retinochoroidal abscess when the fundus view is obscured. (saeed2024auniquecase pages 1-3, braga2024endogenousendophthalmitisdue pages 1-2) Imaging term-name-only: B-scan ultrasonography Human case reports
Differential diagnosis Important mimics include noninfectious uveitis and vitreoretinal lymphoma; distinguishing infection is clinically critical. (asao2025overviewofmicroorganisms pages 26-28) Disease term-name-only: uveitis, vitreoretinal lymphoma Review/contextual expert synthesis
Treatment Standard empiric bacterial therapy remains intravitreal vancomycin plus ceftazidime; intravitreal antibiotics were used in 97.3% of cases in one large cohort. (nowosielski2026visualacuityinfluences pages 1-2, maher2026epidemiologymicrobiologymanagement pages 1-2) NCIT term-name-only: Intravitreal Injection, Vancomycin, Ceftazidime Human cohort; expert-standard practice
Treatment Pars plana vitrectomy is frequently used for severe disease, diagnostic sampling, or poor initial vision; one cohort reported vitrectomy in 41.5% of cases, and benefit appears greatest in light-perception presentations. (maher2026epidemiologymicrobiologymanagement pages 5-8, maher2026epidemiologymicrobiologymanagement pages 1-2) NCIT term-name-only: Vitrectomy, Pars Plana Vitrectomy Human cohort; EVS-aligned expert practice
Treatment Fungal disease often requires combined local and systemic antifungal therapy, with cases using amphotericin B, voriconazole, posaconazole, itraconazole, or isavuconazole. (krohn2024endogenousfungalendophthalmitis pages 1-2) NCIT term-name-only: Amphotericin B, Voriconazole, Posaconazole, Itraconazole, Isavuconazole Human case report
Treatment outcomes Visual improvement is common but incomplete; one cohort found 52.5% improved, while presenting BCVA strongly predicts final outcome. (maher2026epidemiologymicrobiologymanagement pages 5-8, nowosielski2026visualacuityinfluences pages 1-2) Outcome annotation only Human cohorts
Prevention Intracameral antibiotic prophylaxis after cataract surgery is a major preventive strategy; modern post-cataract rates are substantially lower than historical ~0.13%–0.15%. (li2025clinicalretrospectiveanalysis pages 1-2) NCIT term-name-only: Antibiotic Prophylaxis, Intracameral Administration Editorial/surveillance synthesis
Prevention Peri-procedural sterile protocols and microbiological surveillance are central to prevention, especially as post-injection cases rise with anti-VEGF use. (maher2026epidemiologymicrobiologymanagement pages 8-9, maher2026epidemiologymicrobiologymanagement pages 1-2) Public health/clinical process annotation only Human cohort
Genetics No established Mendelian causal gene defines infectious endophthalmitis as a disease entity. N/A for causal Mendelian genes Not applicable
Inheritance No Mendelian inheritance pattern applies; susceptibility is primarily infectious/procedural/systemic-risk based rather than inherited as a monogenic disorder. N/A for AD/AR/X-linked inheritance Not applicable
Pathogenic variants No disease-defining germline pathogenic variant set is established for endophthalmitis. N/A for variant annotation Not applicable
Genetic testing Routine clinical genetic testing (single-gene, panel, WES/WGS, CMA, FISH, mtDNA, repeat expansion) is not standard for diagnosis of infectious endophthalmitis. N/A for genetic testing workflow Not applicable
Model organisms Mouse intravitreal infection models are widely used for bacterial and fungal pathogenesis and treatment studies. (singh2024myeloidcellspecificdeletion pages 1-6, khapuinamai2024unveilingtheinnate pages 1-2) Model annotation only Model organism
Model organisms Zebrafish are comparatively resistant to Staphylococcus aureus endophthalmitis and may model protective innate responses rather than full human disease severity. (maher2026epidemiologymicrobiologymanagement pages 2-5) Model annotation only Model organism
Comparative limitation Animal models reproduce inflammatory and microbiological features but may not fully capture human procedure-related heterogeneity, chronicity, or visual outcome trajectories. (singh2024myeloidcellspecificdeletion pages 1-6, khapuinamai2024unveilingtheinnate pages 1-2) Evidence limitation annotation Model-based inference

Table: This table condenses clinically and biologically relevant endophthalmitis facts into ontology-ready statements with suggested term mappings and evidence types. It is designed to help populate a disease knowledge base while clearly marking uncertain IDs and non-applicable Mendelian genetics fields.

Evidence limitations

Much of contemporary management still rests on the 1995 EVS, observational cohorts, organism-specific case series, and expert practice because randomized trials are difficult for a rare emergency. Incidence, organisms, resistance, and outcomes vary by procedure, geography, referral pattern, and prophylaxis. Recent 2024 mechanistic results are mainly murine and should not be represented as validated human biomarkers or therapies. Likewise, rare-organism case reports demonstrate biological possibility and diagnostic strategy, not frequency or comparative efficacy.

References

  1. (englisch2026microbiologicaletiologyof pages 1-2): Colya N. Englisch, Tim Berger, Fabian N. Fries, Alexander Halfmann, Markus Bischoff, Philip Wakili, Annekatrin Rickmann, Boris V. Stanzel, Eugen Reifschneider, Marc A. Macek, Alaa Din Abdin, Shady Suffo, Loay Daas, Karl T. Boden, Peter Szurman, Berthold Seitz, Sören L. Becker, Clara E. Englisch, and Núria Pérez Guerra. Microbiological etiology of endogenous and exogenous postprocedural endophthalmitis: a 5-year german federal state study. Infection, 54(3):1383-1388, Mar 2026. URL: https://doi.org/10.1007/s15010-026-02763-5, doi:10.1007/s15010-026-02763-5. This article has 0 citations and is from a peer-reviewed journal.

  2. (maher2026epidemiologymicrobiologymanagement pages 1-2): Clare Maher, Brad Guo, Benjamin Sim, Mark Loewenthal, Donna Gillies, and Anthony Hall. Epidemiology, microbiology, management and outcomes of endophthalmitis: an 18 year retrospective observational study at a tertiary referral center in australia. Clinical Ophthalmology, Volume 20:1-11, Feb 2026. URL: https://doi.org/10.2147/opth.s583832, doi:10.2147/opth.s583832. This article has 0 citations and is from a peer-reviewed journal.

  3. (maher2026epidemiologymicrobiologymanagement pages 2-5): Clare Maher, Brad Guo, Benjamin Sim, Mark Loewenthal, Donna Gillies, and Anthony Hall. Epidemiology, microbiology, management and outcomes of endophthalmitis: an 18 year retrospective observational study at a tertiary referral center in australia. Clinical Ophthalmology, Volume 20:1-11, Feb 2026. URL: https://doi.org/10.2147/opth.s583832, doi:10.2147/opth.s583832. This article has 0 citations and is from a peer-reviewed journal.

  4. (singh2024myeloidcellspecificdeletion pages 1-6): Sukhvinder Singh, Pawan Kumar Singh, Zeeshan Ahmad, Susmita Das, Marc Foretz, Benoit Viollet, Shailendra Giri, and Ashok Kumar. Myeloid cell-specific deletion of ampkα1 worsens ocular bacterial infection by skewing macrophage phenotypes. Journal of immunology, 213:1656-1665, Oct 2024. URL: https://doi.org/10.4049/jimmunol.2400282, doi:10.4049/jimmunol.2400282. This article has 3 citations and is from a domain leading peer-reviewed journal.

  5. (khapuinamai2024unveilingtheinnate pages 1-2): Agimanailiu Khapuinamai, Dhanwini Rudraprasad, Suchita Pandey, Dilip Kumar Mishra, and Joveeta Joseph. Unveiling the innate and adaptive immunity interplay: global transcriptomic profiling of the host immune response in candida albicans endophthalmitis in a murine model. Sep 2024. URL: https://doi.org/10.1021/acsomega.4c05081, doi:10.1021/acsomega.4c05081. This article has 4 citations and is from a peer-reviewed journal.

  6. (alshehri2024endogenousendophthalmitisassociated pages 1-2): Abdulaziz M Alshehri. Endogenous endophthalmitis associated with covid-19: a systematic review on its incidence, risk factors, causative organisms, and prognosis. Sep 2024. URL: https://doi.org/10.7759/cureus.70523, doi:10.7759/cureus.70523. This article has 5 citations.

  7. (shah2025riskfactorsfor pages 1-2): Megh K. Shah, Aretha Zhu, Aditya Uppuluri, Roger K. Henry, Marco A. Zarbin, and Neelakshi Bhagat. Risk factors for endogenous endophthalmitis in infectious endocarditis patients. Eye, 39:125-132, Oct 2025. URL: https://doi.org/10.1038/s41433-024-03390-w, doi:10.1038/s41433-024-03390-w. This article has 5 citations and is from a peer-reviewed journal.

  8. (saeed2024auniquecase pages 1-3): Ghazal Talal Saeed, Montaser Nabeeh Al Smady, Gunjan Awatramani, Hessa Alqasimi, Mohammed Amaan Khokar, Mohamed Awad, and Khadija Hafidh. A unique case of hypervirulent klebsiella pneumoniae invasive syndrome with endogenous endophthalmitis and left renal vein thrombosis without liver abscess. European Journal of Case Reports in Internal Medicine, Oct 2024. URL: https://doi.org/10.12890/2024_004927, doi:10.12890/2024_004927. This article has 5 citations.

  9. (braga2024endogenousendophthalmitisdue pages 1-2): João Pedro Romero Braga, Victor C. F. Bellanda, Moises Moura de Lucena, Francyne Veiga Reis, and Rodrigo Jorge. Endogenous endophthalmitis due to escherichia coli: a case report. Arquivos Brasileiros de Oftalmologia, Mar 2024. URL: https://doi.org/10.5935/0004-2749.2023-0066, doi:10.5935/0004-2749.2023-0066. This article has 3 citations and is from a peer-reviewed journal.

  10. (li2025clinicalretrospectiveanalysis pages 1-2): Chunhui Li, Zheyi Yan, Guohong Zhou, Yan Gao, and Peini Cheng. Clinical retrospective analysis of 218 cases of infectious endophthalmitis. BMC Ophthalmology, Jun 2025. URL: https://doi.org/10.1186/s12886-025-04142-4, doi:10.1186/s12886-025-04142-4. This article has 4 citations and is from a peer-reviewed journal.

  11. (wu2024systematicinflammatoryindicators pages 1-2): Donghai Wu, Yuan Lin, Huping Wu, and Jinhong Cai. Systematic inflammatory indicators and clinical management of exogenous endophthalmitis due to metal penetrating injury of eyeball. Frontiers in Medicine, Dec 2024. URL: https://doi.org/10.3389/fmed.2024.1466530, doi:10.3389/fmed.2024.1466530. This article has 3 citations.

  12. (nowosielski2026visualacuityinfluences pages 1-2): Yvonne Nowosielski, Charlotte Erlacher, Sarah Maier, Teresa Rauchegger, Alexander Franchi, and Matus Rehak. Visual acuity influences visual outcome in endophthalmitis: a 10-year retrospective observational cohort analysis. Ophthalmology and Therapy, Aug 2026. URL: https://doi.org/10.1007/s40123-026-01468-0, doi:10.1007/s40123-026-01468-0. This article has 0 citations and is from a peer-reviewed journal.

  13. (krohn2024endogenousfungalendophthalmitis pages 1-2): Jørgen Krohn, Øystein A. Power, Haima Mylvaganam, Andreas J. Askim, Jarle B. Arnes, and Bjørn Blomberg. Endogenous fungal endophthalmitis caused by cladophialophora devriesii: report of a case and literature review. Journal of Ophthalmic Inflammation and Infection, Jun 2024. URL: https://doi.org/10.1186/s12348-024-00408-y, doi:10.1186/s12348-024-00408-y. This article has 1 citations and is from a peer-reviewed journal.

  14. (maher2026epidemiologymicrobiologymanagement pages 8-9): Clare Maher, Brad Guo, Benjamin Sim, Mark Loewenthal, Donna Gillies, and Anthony Hall. Epidemiology, microbiology, management and outcomes of endophthalmitis: an 18 year retrospective observational study at a tertiary referral center in australia. Clinical Ophthalmology, Volume 20:1-11, Feb 2026. URL: https://doi.org/10.2147/opth.s583832, doi:10.2147/opth.s583832. This article has 0 citations and is from a peer-reviewed journal.

  15. (asao2025overviewofmicroorganisms pages 26-28): Kazunobu Asao and Noriyasu Hashida. Overview of microorganisms: bacterial microbiome, mycobiome, virome identified using next-generation sequencing, and their application to ophthalmic diseases. Jun 2025. URL: https://doi.org/10.3390/microorganisms13061300, doi:10.3390/microorganisms13061300. This article has 6 citations.

  16. (maher2026epidemiologymicrobiologymanagement pages 5-8): Clare Maher, Brad Guo, Benjamin Sim, Mark Loewenthal, Donna Gillies, and Anthony Hall. Epidemiology, microbiology, management and outcomes of endophthalmitis: an 18 year retrospective observational study at a tertiary referral center in australia. Clinical Ophthalmology, Volume 20:1-11, Feb 2026. URL: https://doi.org/10.2147/opth.s583832, doi:10.2147/opth.s583832. This article has 0 citations and is from a peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 13
On topic 2
Off topic 0

All extracted references resolved successfully.